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ABSTRACT 
In the UK ovarian cancer is the fifth most common cancer in females and after uterine 
cancer, the second most common gynaecological cancer. There were 6,596 new cases 
diagnosed in the UK in 2006.  The majority of women who develop ovarian cancer have 
few symptoms until the cancer has spread. A systematic review of published literature 
was performed to include randomised control trials, case control or cohort studies.  It is 
apparent from the literature on ovarian cancer screening that internationally extensive 
research is performed however, there is lack of consensus on who to offer screening to, 
and the most efficacious way of offering it. Annual screening was found to be 
inadequate for early cancer detection as several studies report advanced stage disease or 
found that women were developing symptoms in the interim period of screening visits.  
 
The retrospective studies performed at Milton Keynes Hospital demonstrated that 
ovarian cancer affects a wide age range with many women having no family history of 
ovarian or breast cancer. Many cases were found to have early stage ovarian cancer 
however, the largest group of women were found to have extensive metastatic disease at 
time of diagnosis. 80% of cases reviewed experienced abdominal or pelvic pains often 
with distension. Five patients were found to have a CA125 value in the normal range, 
one of which had advanced disease, indicating the limitations of this biomarker. The 
impact and costs associated with screening in the NHS setting vary considerably with 
inclusion criteria used. The UK National Screening Committee will have to decide once 
the findings of UKCTOCS are published in 2010/11 as to the cost benefit of offering 
NHS based ovarian cancer screening. An annual cost of at least £1.3 million should be 
expected per NHS trust, in addition to individual trusts needs for equipment, staff and 
additional facilities required to offer such screening. 
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1.1 What is Cancer? 
Cancer is broadly characterised by unregulated cell growth leading to invasion of 
surrounding tissues and occasionally with metastatic spread (King, 2000).  Any growth 
of one or, occasionally, a few cell types at the expense of others that disrupt the normal 
interrelationships between different cell types and their extracellular matrix, is cancer. 
The acquisition of invasive properties is what distinguishes malignant cells from benign 
cells, whilst the primary cause of clinical problems and death is due to metastatic 
disease.  At a molecular level, animal and cell biological experiments have identified 
DNA (deoxyribonucleic acid) sequences and proteins directly relevant to human 
cancers. However, no single model explains the pathogenesis of all human cancers.  
 
The terms cancer, tumour and neoplasm are often used in an interchangeable way often 
causing confusion. It is important to understand that neoplasm means new growth 
without qualifying the nature of that growth whereas tumour can be applied to both 
benign and malignant growths.  A clinician would consider an increased cell mass on its 
own to be a benign, easily controllable growth and not cancer.  An abnormal mass of 
tissue that is uncontrolled and progressive resulting from excessive cell division is a 
process of tumorigenesis. Tumorigenesis is considered a compilation of complex 
genetic diseases that regulate cell growth, proliferation and differentiation (King, 2000). 
Benign growths are sometimes, but not always precursors of malignant growths. Colon 
and thyroid cancer are examples where benign growths turn malignant, whereas benign 
prostate and breast growths are not precursors of malignant growths. Table 1.1 provides 
distinctions between benign and malignant growths. 
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Table 1.1 Comparison of benign and malignant growths (King, 2000) 
Diagnostic imaging is the routine method of detecting a cancer and staging of disease, 
with histopathology characterisation following an excision or biopsy. Diagnosis of 
cancer not only relies on the appearance of the cells but also on the tissue architecture as 
summarised in Figure 1.1. 
   Normal 
       
       
 
       
       
       
 
   Cancer 
 
 
 
 
 
 
Variable cell and nuclear shape 
Large nucleus 
No basement membrane 
Disrupted tissue organisation 
Altered epithelium/stromal ratio 
Invasion of blood vessels and lymphatics 
 
Organised epithelium 
Cell Junctions 
Regular and small nucleus 
 
Basement membrane 
Organised stromal cells 
Figure 1.1 Features of normal and cancer glandular epithelium (King, 2000) 
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Cancers are described according to their cell origin and the tissue in which they arise: 
Epithelium (carcinoma) 
 Glandular eg. Prostate: adenocarcinoma 
 Squamous eg. Cervix: carcinoma 
Mesenchyme (sarcoma) 
 Smooth muscle: leiomyosarcoma – benign hyperproliferation is called a 
leiomyoma (fibroid). 
 Bone: Osteosarcoma 
 Fat cells: Liposarcoma – benign hyperproliferation is called a lipoma. 
Nervous system 
 Eye: retinoblastoma 
 Astrocytes: astrocytoma 
White blood cells (leukaemia) 
 Myeloid cells: myelocytic leukaemia 
 Lymphocytes: lymphocytic leukaemia 
 Lymphoma: solid tumour derived from B and T lymphocytes 
 
Carcinogenesis involves a series of changes that are reflected in an increasing departure 
from normal morphology with uncontrolled and often rapid proliferation of cells leading 
to malignant tumours.  Pathology helps to define boundaries in this sequence of events, 
but as changes continue to occur after a cancer has formed, cell characterisation also has 
a role to play as a prognostic tool to determine the likely course of the disease. 
Pathology can also be used for monitoring the completeness of surgery as cancers can 
have ill-defined margins, microscopic analysis of an excised lump can tell whether or 
not cancer cells occur at its edges and provide evidence as to efficiency of removal. 
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1.2 Ovarian Cancer 
It is important to realise that ovarian cancer is not a single disease as there are many 
types, each with their own characteristics and behaviour from an assortment of different 
cell types. Its pathogenesis is still indefinite but it is possible to catalogue tumours into 
three groups benign, intermediate and malignant. Surface epithelial carcinomas are the 
most common type of ovarian cancer with Figure 1.2 providing identification of a 
healthy ovary structure and stages of ovulation. 
 
 
 
Figure 1.2 Main structure of a healthy ovary and ovulation (Herbrandson, 2005) 
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1.2.1 Classification and Stages of Disease 
Ovarian cancer is classified according to the histology of the tumour. Lesions differ 
significantly in clinical features, management and prognosis. There are three different 
types of ovarian cancer. The type is determined by the location in the ovary where the 
cancer develops (Mougeot et al, 2006): 
 
Epithelial  Serous 
  Mucinous 
  Endometrioid  
  Clear cell 
  Papillary serous 
  Brenner cell  
  Undifferentiated adenocarcinomas and sarcomas 
 
Germ Cell  Teratomas 
  Mature teratomas 
  Immature teratomas 
  Struma ovarii 
  Carcinoid 
  Dysgerminoma 
  Embryonal cell carcinoma 
  Endodermal sinus tumour 
  Primary choriocarcinoma 
  Gonadoblastoma 
 
Specialised stromal cell cancers Granulosa cell tumour 
  Theca cell tumour 
  Sertoli-leydig cell tumour 
  Hilar cell tumour 
 
 
Cancer that develops on the 
surface of the ovary 
 
85-95% of all ovarian cancers 
Cancer that develops in the 
supportive tissue of the ovary 
 
5-8% of all ovarian cancers 
Cancer that develops in an egg 
cell produced in the ovary 
 
Most typically occurs in young 
girls / women 
 
<5% of all ovarian cancers 
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Epithelial ovarian cancer is staged using the International Federation of Gynaecology 
and Obstetrics (FIGO) stage at initial presentation as shown in Table 1.2.  In the first 
stage of the disease the tumour is concentrated only in the ovaries, Stage II the growth is 
limited to the ovaries with pelvic extensions, Stage III the growth involves the ovaries 
with peritoneal implants outside the pelvis and finally, Stage IV the growth involves the 
ovaries with distant metastases.   
 
Table 1.2 FIGO Staging System for Ovarian Cancer (International Federation of Gynaecology and 
Obstetrics, 2010) 
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The stage of disease is determined through diagnostic imaging and at surgery through 
examination of the primary tumour, assessing lymph node involvement and whether the 
cancer has metastasised to other parts of the body. The prognosis based on the type of 
tumour, stage of cancer and patient‟s overall health means a health professional can 
recommend the most effective treatment options (International Federation of 
Gynaecology and Obstetrics, 2010). 
 
1.2.2 Incidence, Mortality and Symptoms 
In the UK ovarian cancer is the fifth most common cancer in females and after uterine 
cancer, the second most common gynaecological cancer. There were 6,596 new cases 
diagnosed in the UK in 2006 and it has been estimated, based on incidence and 
mortality data from 2001-2005 (Cancer Research UK, 2009), that the lifetime risk of 
developing ovarian cancer is 1 in 50 for women in the UK.  Over 80% of ovarian cancer 
cases are diagnosed in women over 50yrs of age with a steep increase in incidence in 
postmenopausal women (aged 55yrs and over), as seen in Figure 1.3. 
Figure 1.3 Number of new cases and age-specific incidence rates in UK, 2006 (Cancer Research 
UK, 2009) 
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Ovarian cancer accounts for more deaths than all the other gynaecological cancers 
combined. 4,317 UK women died from ovarian cancer in 2007, accounting for around 
6% of all female deaths from cancer (Cancer Research UK, 2009). The number of 
deaths and the rates for the constituent countries of the UK are shown below in Table 
1.3. 
Table 1.3 Number of deaths and mortality rates of ovarian cancer (Cancer Research UK, 2009) 
 
The majority of women who develop ovarian cancer have few symptoms until the 
cancer has spread and by then treatment is more difficult.  It used to be believed that 
ovarian cancer had no symptoms at all, however, the symptoms experienced are vague 
and difficult to recognise particularly in the early stages of the disease. Symptoms 
known to be related with the disease include (Rufford et al., 2007): 
 
 
 
 
Research has shown that the advanced stage at diagnosis of ovarian cancer is thought to 
be directly responsible for the high case fatality ratio, as early-stage disease (FIGO 
Stage I) is associated with a five-year survival of over 85% as shown in Figure 1.4. For 
women diagnosed with distant metastases (FIGO Stage IV) the five-year survival rate is 
around 15%. 
 England Wales Scotland N.Ireland UK 
Deaths 
Females 3,554 255 392 116 4,317 
Crude rate per 100,000 population 
Females 13.7 16.7 14.7 12.9 13.9 
Age-Standardised rate (European) per 100,000 population 
Females 9.7 11.0 10.1 10.5 9.8 
o Pain during intercourse 
o Nausea / weight loss 
o Loss of appetite / tiredness    
 
o Pelvic pain / bloating 
o Urinary urgency or frequency of micturition 
o Constipation / irregular periods 
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Five-year survival rates are also related to the age at which the disease is diagnosed with 
women under the age of 50 years likely to be diagnosed with local disease and women 
over 65 years are more likely to have distant metastases. Figure 1.5 demonstrates the 
difference from women aged 15-39 having a five-year survival rate of nearly 70% to 
that of 12% survival if diagnosed between 80-89 years of age. 
Figure 1.4 Correlation of Stage and 5-year survival in ovarian cancer (Menon and Jacobs, 2002) 
Figure 1.5 Age at diagnosis and five-year survival rates (Cancer Research UK, 2009) 
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1.2.3 Familial and Sporadic Ovarian Cancer 
Around 5 – 10% of all cases of ovarian cancer are the result of an inherited gene or 
genes. There are three types of family history of ovarian cancer (Sekine, 2001): 
 Hereditary site-specific  
 Lynch syndrome II (MSH2 and MLH1) 
 Hereditary breast / ovarian carcinoma (BRCA1 and BRCA2 tumour suppressor 
genes). 
Breast cancer genes (BRCA) are tumour suppressor genes that inhibit the growth of 
cancer cells. Mutations of BRCA1 or BRCA2 genes express proteins that have different 
functions in ovarian carcinogenesis. Nearly all site specific hereditary ovarian 
carcinoma is a result of BRCA1 and BRCA2 mutations.  BRCA1 is implicated in up to 
90% of breast-ovarian cancer families with two or more cases of early onset breast 
cancer and two or more cases of ovarian carcinoma.  BRCA2 mutations account for 
fewer than 10% of cases of hereditary breast-ovarian carcinoma.  The risk of developing 
ovarian cancer to age 70 in those BRCA1 carriers is up to 50%. An overview of the 
genes implicated in hereditary ovarian cancer is provided in Table 1.4.   
 
Table 1.4 Brief overview of genes implicated in hereditary ovarian cancer (Kasprzak et al, 1999) 
Gene 
(syndrome name) 
% of inherited 
cases 
associated with 
gene mutation 
Type of ovarian 
cancer 
Risk of 
ovarian 
cancer to 
age 70 (%) 
Other features of syndrome 
BRCA1 (hereditary 
breast and ovarian 
cancer) 
75 Serous ovarian 
carcinoma 
20-50 Cancer of breast, fallopian 
tube 
BRCA2 (hereditary 
breast and ovarian 
cancer) 
10 Serous ovarian 
carcinoma 
10-30 Cancer of breast, prostate, 
pancreas, head and neck 
MMR genes (hereditary 
non-polyposis 
colorectal cancer) 
5-10 Ovarian carcinoma 
– all types 
<10 Cancer of colorectum, 
endometrium, stomach, 
urinary tract and small bowel 
STK11 (Peutz-Jeghers) <1 Granulosa cell 
tumour 
<2 Mucosal freckles, 
gastrointestinal polyps and 
breast cancer 
PTEN (Cowden 
disease) 
<1 Ovarian carcinoma <2 Mucocutaneous lesions, 
breast cancer, thyroid cancer 
PTC (Gorlin syndrome) <1 Ovarian 
fibrosarcoma 
<1 Basal cell carcinoma 
EXT1, EXT2, EXT3 
(Ollier‟s disease) 
<1 Granulosa cell 
tumour 
<1 Osteochondromatosis 
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Kasprzak (1999) found that hereditary forms of ovarian carcinoma occur at an earlier 
age than sporadic disease, with a mean age of five years younger onset in hereditary 
ovarian carcinoma found.  Sporadic ovarian cancer and hereditary ovarian cancer are 
not significantly different as shown in Table 1.5. Kasprzak (1999) also found similar 
prognosis in hereditary and sporadic ovarian carcinoma. 
 
Table 1.5 Main differences in BRCA mutation between sporadic and inherited ovarian cancer 
(Wong, 2003) 
Sporadic Ovarian Cancer Inherited Ovarian Cancer 
May result also in loss of BRCA 
functions through inactivation of these 
genes. 
Ovarian cancers arising from BRCA1 or 
BRCA2 mutations positive families are 
more likely to be invasive high grade and 
of serous histological type. Mutations are rare 
Loss of BRCA function 
 
No strong environmental risk factors are known, and after age, the most important risk 
factor is a family history of the disease. However, factors known to be associated with 
the development of epithelial ovarian cancer include (Sekine, 2001): 
Reproductive Factors Early menarche 
 Late menopause 
 Infertility, null parity 
Demographics White or European 
 Jewish descent 
 Residence in industrialised nation (except Japan) 
Diet High fat intake 
 High coffee intake 
 Low fibre 
 Low vitamin A 
Environmental exposure Perineal talc use 
 Asbestos radiation 
 Viral infection 
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1.3 Detection and Diagnosis of Ovarian Cancer 
 
Ovarian cancer may be suspected if any of the previously described symptoms are 
experienced or a pelvic mass is felt by a clinician. Typically in the NHS setting there are 
two main methods of investigating ovarian pathology with the aim of detecting ovarian 
cancer, an imaging modality and serum based biomarker analysis.  
1.3.1 Imaging Diagnosis 
Several modalities exist capable of imaging normal and abnormal ovaries, including 
ultrasound, computerised tomography (CT), magnetic resonance imaging (MRI), 
radioimmunoscintography and positron-emission tomography scanning.  At present 
ultrasound is widely available for diagnostic use as a non-ionising and cost effective 
imaging modality.  Particularly through the introduction of transvaginal ultrasound 
(TVS), image quality has greatly improved with higher frequencies used during 
scanning (Van Nagell et al, 2007). Ultrasound examinations are easily referred for by 
general practitioners and gynaecologists as a first-line imaging modality for suspected 
gynaecological pathology.  The size, appearance and vascularity of the ovary can be 
assessed without the need of intravenous contrast as used in CT and MRI. Normal 
physiological events can be observed, particularly in premenopausal women during 
active ovarian follicle formation. Ultrasound detects both benign and malignant lesions 
and therefore, appearances and criteria for diagnosis of an abnormal ovary can 
therefore, vary with menopausal status and age.  Currently standardised ultrasound 
criteria for distinguishing between benign and malignant conditions has not been 
universally accepted (DePriest and DeSimone, 2003); however, through the 
morphological characteristics of the ovary being imaged, many investigators have 
developed diagnostic criteria scoring systems to systematically assess the risk of 
malignancy. Commonly used complex ovarian morphology classification criteria 
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include measurements of the ovary, echogenicity of solid masses, cyst wall thickness, 
presence of septae or papillary growths, with an example of this shown in Appendix G. 
Figures 1.6 and 1.7 provide ultrasound examples of normal and abnormal appearing 
ovaries on transvaginal scanning.  Follicular detail in the normal appearing ovary can be 
seen in Figure 1.6, whilst in Figure 1.7 there is evidence of a large complex part-solid / 
part-cystic tumour with abnormal vascularity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Ultrasound image of a normal appearing ovary (Harris, 2002) 
Figure 1.7 Ultrasound image of a complex adnexal mass with multiple septations, 
solid components and abnormal vascularity suggesting malignancy (Fishman et 
al, 2005) 
  
 
21 
Colour Doppler imaging is a recently developed tool used in addition to grey-scale 
ultrasound that enables blood flow imaging in vessels and a trace of the pattern of flow. 
This technique can provide additional important information regarding the risk of 
malignancy as ovarian neoplasm angiogenesis leads to the formation of abnormal 
vessels with a lower impedance to blood flow. This second-line technique can improve 
the specificity of ultrasound by enhancing the ability to discriminate benign from 
malignant ovarian pathology (Fishman et al, 2005). Figure 1.8 provides a transvaginal 
scan image of a solid ovarian mass with low impedance flow using colour Doppler 
imaging, which is a clear cell carcinoma of the ovary. 
 
Following an abnormal pelvic tumour detected by ultrasound a CT or MRI is routinely 
performed to stage the disease and / or to investigate the tumour further prior to biopsy 
or surgical removal.   
 
Figure 1.8 Transvaginal scan of a solid ovarian mass with low impedance flow (Fleischer, 2009) 
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1.3.2 Biomarkers 
An ideal tumour marker would change in concentration with the amount of malignant 
tissue present and be specific for the cancer for which it is testing, without being present 
in any other conditions. A marker can be a protein, gene, proteomic pattern, a cell type 
or an abnormality. Tumour markers can be detected in elevated amounts in serum 
(blood or plasma), body tissues and urine (Gogoi et al, 2006).  
 
Ovarian tumours are known to produce a number of cell-surface antigens and serum 
proteins that can be measured through a blood test and laboratory assay of the serum. 
The most common serum based biomarker for ovarian cancer detection is cancer 
antigen 125 (CA125). This tumour marker is a chemical that is secreted by cancer cells 
and circulates in the blood stream. Women with ovarian cancer tend to have higher 
levels of CA125 in their blood, compared to women who do not have ovarian cancer. 
However, CA125 has known limitations with elevated levels found in 61-96% of 
routinely diagnosed epithelial ovarian cancers and in 29-75% of cancers diagnosed at 
the earliest stage (Menon & Jacobs, 2002). The specificity of CA125 is also often 
limited with elevated levels found in other cancers and benign diseases as outlined in 
Table 1.6.   
 
Table 1.6 Causes of elevated CA125 levels  (Menon and Jacobs, 2002) 
Cancers Benign Disease 
Ovarian Benign ovarian disease 
Endometrial Uterine leiomyomas 
Cervical Endometriosis 
Lung Pregnancy 
Breast Menstruation 
Colorectal Pelvic inflammatory disease 
Pancreatic Pancreatitis 
 Hepatitis 
 Hypothyroidism 
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It is clear from Menon & Jacobs (2002) that premenopausal women may often have 
elevated levels of CA125 due to benign ovarian disease, fibroids, endometriosis and 
pelvic inflammatory disease. Therefore, to summarise what CA125 offers: 
 Around 61-96% of all women with ovarian cancer will have elevated CA125. 
 Around 29-75% of all women with early stage ovarian cancer will have elevated 
CA125. 
 Premenopausal women may also have elevated CA125 due to other benign 
causes. 
Despite these limitations CA125 is the most common and routinely used biomarker in 
clinical practice for the detection of ovarian cancer. Extensive research is ongoing for 
new and clinically more useful biomarkers for early ovarian cancer detection (Gogoi et 
al, 2006). 
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1.4 Screening 
 
When investigating the impact of screening it is important to understand what certain 
terminology means. The UK National Screening Committee (2009) defines screening as  
“a process of identifying apparently healthy people who may be at increased risk of a 
disease or condition. They can then be offered information, further tests and appropriate 
treatment to reduce their risk and/or any complications arising from the disease or 
condition.” 
 
In order for screening to have the potential to save lives and improve quality of life, 
early diagnosis of serious conditions is paramount. Diagnosis is defined as the process 
of identifying a medical condition or disease by its signs, symptoms, and from the 
results of various diagnostic procedures (Harris, 2002).  Several criteria that must be 
satisfied in the design and clinical application of an early-detection programme are 
described by Teneriello and Park (1995):  
o The cancer has an identifiable phase of early invasive disease, such that the 
outcome of patients is improved if the disease is detected at an early stage. 
o The disease itself must pose a significant medical threat to justify the expense 
and effort of a population-based screening programme. 
o The testing modality should be sensitive enough to detect small-volume disease 
states, cost efficient, widely available for use and relatively easy to perform. 
o Specificity must be maintained so that individuals without disease can be 
accurately identified. 
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1.4.1 Sensitivity and Specificity 
Establishing the benefits and harms of a screening test is related to its ability to 
distinguish between those who have a certain condition and those who do not. This can 
be expressed as the sensitivity and specificity of the test. When the test is undertaken, 
four outcomes are possible in the context of cancer screening: 
1. True-positive(a): the test correctly identifies those people with cancer. 
2. False-positive(b): the test is positive when in fact the person does not have 
cancer. 
3. False-negative(c): the test is negative when in fact the person has cancer. 
4. True-negative(d): the test is negative and the person does not have cancer. 
 
Table 1.7 provides an overview of calculating the performance of a screening test. A 
high sensitivity and specificity of a screening test is achieved through discriminating 
well between diseased and healthy participants.  
 
Table 1.7 Calculating the performance of a screening test (Bell et al., 1998) 
The Positive Predictive Value (PPV) is the percentage of patients with a positive result 
who actually have the condition. The PPV can be calculated by: 
Number of true positives 
Number of true positives + Number of false positives 
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1.4.2 Ovarian Cancer Screening 
The current position of the UK National Screening Committee (2009) is that ovarian 
cancer screening should not be offered except in the context of the Medical Research 
Council randomised controlled trial. This policy is due to be reviewed in 2010/11 
following the report of the UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS). The aim of ovarian cancer screening is to reduce mortality and morbidity 
from ovarian cancer by detecting it at an early stage when treatment may be more 
effective. Two screening tests have evolved through years of research for the early 
detection of ovarian cancer (Menon and Jacobs, 2002): 
1. Detection of ovarian morphological abnormalities by transvaginal ultrasound. 
2. Measurement of serum tumour markers produced by, or in response to, ovarian 
cancer. 
Based on these two screening tests, three ovarian cancer screening strategies have 
emerged as shown in Figure 1.9. 
   Primary Test 
   If
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y
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t 
is
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al
  Secondary Test 
 
Multimodal Strategy       CA125 TVS + CA125 
   
Ultrasound Strategy TVS Repeat TVS 
   
Combined Strategy CA125 + TVS Repeat TVS + 
CA125 or TVS or 
CA125 alone 
 
 
The detection of ovarian cancer regardless of screening strategy must aim for a high 
sensitivity (≥90%) and an acceptable false-positive rate. As shown in Figure 1.10, the 
data from prospective studies of ovarian cancer screening in the general population 
suggest that ultrasound offers greater sensitivity as a first-line test and multimodal 
screening (MM) particularly using a risk of cancer algorithm (ROC), has superior 
specificity and positive predictive values. 
Figure 1.9 Screening Strategies for Ovarian Cancer (Menon and Jacobs, 2002) 
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1.4.3 Screening Population 
Women in the United Kingdom who are determined to be at high risk of developing 
ovarian cancer and who are unsuitable or unwilling to undergo prophylactic bilateral 
salpingo-oophorectomy are currently being offered annual screening for ovarian cancer 
through the UK Familial Ovarian Cancer Screening Study (UKFOCSS) led by the 
University College London. There are two main groups of women who are at increased 
risk of developing ovarian cancer. Firstly, women over the age of 50 with no significant 
family history of ovarian cancer and secondly, women with a strong family history of 
breast and/or ovarian cancer.  The median age for diagnosis of ovarian cancer in women 
over the age of 50 with no significant family history of the disease is 59, with a lifetime 
risk of developing the cancer being 1.3% in this population.  Those with a strong family 
history of the disease will usually have a lifetime risk of developing ovarian cancer of 
>15% with a median age for diagnosis being 51.9 years (Drescher et al., 2004). Menon 
and Jacobs (2002) recommend screening women at increased risk from the age of 35, 
even though screening premenopausal women is associated with an increase in false-
positive CA125 levels and benign ultrasound abnormalities. 
Figure 1.10 Performance characteristics of ovarian cancer screening strategies (Menon and Jacobs, 
2002) 
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1.4.4 Treatment 
Treatment options available vary with the type of ovarian cancer, stage at diagnosis and 
patient‟s general health. Almost all women with ovarian cancer will need surgery and 
the amount required will vary with stage and type of ovarian cancer. Women with 
borderline tumours or low-grade FIGO Stage I disease may need no further treatment, 
although some may have radiotherapy to the pelvic area.  Chemotherapy is used in most 
other cases.  Despite aggressive treatment 70% of patients who present initially with a 
FIGO Stage III or IV disease, at best will have a five year survival rate in the range of 
15-25% (Menon and Jacobs, 2002).  Chemotherapy is often used in Stage IV disease 
prior to surgery to attempt to reduce the size of the tumour or if surgery is not 
appropriate, to relieve symptoms. 
 
1.4.5 Milton Keynes Hospital NHS Foundation Trust 
Approximately 228,400 people live and over 130,000 people work in Milton Keynes. In 
2007 Milton Keynes Hospital became a Foundation Trust, meaning that its patients, the 
public and staff can now be more responsive to the needs and wishes of people living in 
Milton Keynes and the surrounding areas. Services offered by the Trust include all 
medical, surgical and child health emergency admissions with increasing specialist 
services, including cancer, cardiology, oral surgery and neonatal care. Over 300,000 
people every year are provided a broad range of general medical and surgical services, 
including accident and emergency. Screening currently offered at Milton Keynes 
Hospital includes breast, cervical and bowel cancer, fetal anomaly, infectious diseases 
in pregnancy and newborn hearing. The Department of Health and South Central 
Strategic Health Authority provide strategic direction for this medium sized hospital.   
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1.5 Aims and Objectives 
 
The aim of this project is to investigate the feasibility of an NHS based ovarian cancer 
screening programme with regard to current clinical evidence, resources required, costs 
involved and implications for a local NHS Foundation Trust.  In order to achieve this 
aim a systematic literature search will be performed analysing variations in methods 
used for screening and inclusion criteria adhered to.  A retrospective study of ovarian 
cancer cases diagnosed at Milton Keynes Hospital will provide an overview of the 
clinical problem that ovarian cancer presents in its stage at diagnosis and symptoms 
experienced by women. Confirmed and suspected cases of ovarian cancer at Milton 
Keynes Hospital will be analysed with key findings and cases documented where initial 
imaging was unable to confirm benign ovarian lesions. Finally, through exploring 
recommended NHS costings, the financial impact of offering ovarian cancer screening 
will be predicted at a local level based on literature reviewed and findings from the 
retrospective study of confirmed ovarian cancer cases at Milton Keynes Hospital.   
 
The objectives of this thesis have been listed using their chapter headings: 
 
Chapter 2 – Screening for Ovarian Cancer: A Systematic Literature Review 
1. Perform a systematic literature review of available publications investigating ovarian 
cancer screening and critically appraise studies included. 
2. Compare ovarian cancer screening with currently offered cancer-screening 
programmes. 
3. Investigate variations in screening methods used. 
4. Investigate variations in high risk of ovarian cancer classification / study inclusion 
criteria. 
5. Investigate psychosocial constructs associated with participants involved in ovarian 
cancer screening studies. 
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Chapter 3 – Retrospective Study of Confirmed and Suspected Ovarian Cancer 
Cases 
6. Perform a retrospective study of patients diagnosed with ovarian cancer at Milton 
Keynes Hospital to establish stage at diagnosis, age and family history of the disease.  
7. Investigate the role and diagnostic accuracy of imaging when suspecting ovarian 
cancer to establish how many cases with suspected malignancy through imaging 
alone resulted in benign pathology. 
 
Chapter 4 – Cost Analysis of Ovarian Cancer Screening 
8. Investigate NHS based cancer screening programme costs.  
9. Provide a proposed cost analysis of NHS implemented ovarian cancer screening. 
10. Incorporate experience from a current ovarian cancer screening study. 
11. Investigate the impact on Milton Keynes Hospital in offering an ovarian cancer-
screening programme. 
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1.6 Thesis Methodology 
 
To investigate the impact of NHS based ovarian cancer screening several research 
methods have been used in order to provide evidence based conclusions and justified 
recommendations. As NHS based ovarian cancer screening is not currently 
recommended by the UK National Screening Committee a systematic literature review 
has been performed of published studies investigating ovarian cancer screening with 
variations in methods used analysed.  A systematic literature review was chosen as this 
research method provides a comprehensive appraisal of large quantities of research, 
which as part of the systematic process is subject to a critical appraisal meaning 
evidence that is of an inadequate quality is excluded from further review.  The literature 
review provides recent high quality ovarian cancer screening studies and an overview of 
variations in screening methods and inclusion criteria used.  
 
To establish the impact of NHS based ovarian cancer screening at a local level in Milton 
Keynes Hospital NHS Foundation Trust, a retrospective study of patients diagnosed 
with ovarian cancer at Milton Keynes Hospital was performed.  This study was firstly, 
aimed to provide up to date information into the clinical problem that ovarian cancer 
presents in its stage at diagnosis, age and the number of women diagnosed with the 
disease in a local Hospital.  Secondly, as ovarian cancer diagnosis involves an imaging 
modality a further retrospective study investigated the diagnostic accuracy of ovarian 
pathology detection and possible diagnostic limitations of lesion characterisation. 
Finally, through performing the systematic literature review and local retrospective 
studies, a cost analysis based on current NHS recommendations has been provided with 
scenarios based on current UK screening studies and literature reviewed.  The impact at 
a local level and cost associated with ovarian cancer screening have been explored 
should implementation within the NHS begin. 
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2 SCREENING FOR OVARIAN 
CANCER: A SYSTEMATIC 
LITERATURE REVIEW 
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2.1 Benefit of Systematic Literature Reviews 
Detection of early serious conditions provides the opportunity to start effective 
treatment or intervention before the disease or condition progresses. Women who have 
screen detected ovarian cancer have the potential for their outcome to be improved with 
effective treatment, prior to presenting with symptoms.  The National Health Service 
has a number of screening programmes in place proving successful in the early 
identification of diseases and conditions including breast cancer, bowel cancer, cervical 
cancer, cystic fibrosis, sickle cell anaemia, Down‟s syndrome and Chlamydia.  The 
National Screening Committee (NSC) was created in 1996 to assess proposed new 
screening programmes and advise government health ministers on all aspects of 
screening policy. This advice is often based on Health Technology Assessment (HTA) 
reports, part of the National Institute for Health Research, providing independent 
scientific research. The HTA programme aims to ensure that high quality research 
information on the costs, effectiveness and broader impact of health technologies is 
produced in the most efficient way for those who use, manage and work in the NHS 
(National Institute for Health Research, 2010).  As ovarian cancer screening is not 
currently recommended by the NSC except in the context of the Medical Research 
Council randomised control trial, a systematic literature review evaluating ovarian 
cancer screening would be of interest in providing a current overview of screening 
methods used by high quality studies and what sensitivity and specificity levels were 
able to be achieved.  
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The National Institute for Health and Clinical Excellence (NICE) is an independent 
organisation responsible for providing national guidance on promoting good health and 
preventing and treating ill health.  NICE guidance aims to ensure that the promotion of 
good health and patient care in local health communities is in line with the best 
available evidence of effectiveness and cost effectiveness. Therefore, a systematic 
literature review investigating ovarian cancer screening would be of interest to NICE as 
the evidence provided could lead to patient benefit through improved patient outcomes 
and efficient use of NHS resources through analysis of screening studies performed. 
2.1.1 Characteristics of Systematic Reviews 
There is a growing requirement that clinical practice is based on evidence due to the 
vast array of health care literature and products available. There are therefore, 
difficulties in ensuring that clinicians base decisions on reliable sources of research, as 
often studies produce contradictory results. Systematic reviews provide a 
comprehensive appraisal of large quantities of research, which as part of the systematic 
process is subject to a critical appraisal. There are certain key characteristics of a 
systematic review that increase the power and decrease the bias of research findings.  
This is because a systematic review (Trinder and Reynolds, 2000): 
o Is based on an exhaustive search for all the relevant literature. 
o Uses explicit and validated criteria for excluding evidence that is of inadequate 
quality. 
o Cites the evidence that has been excluded. 
o Uses valid and explicit methods for combining data, a process called meta-
analysis.                                 
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2.2 Study Design 
The search for published literature involves two main electronic bibliographic databases 
with studies found subject to a critical appraisal as part of the systematic process. The 
two electronic bibliographic databases were chosen due to their extensive coverage of 
scientific, technical, medical and social sciences research. The Cochrane Library 
provides a collection of databases containing high-quality independent evidence to 
inform healthcare decision-making. Current evidence is available through sources in 
systematic reviews, technology assessments, economic evaluations and clinical trials. 
SCOPUS offers the world‟s biggest abstract and citation database covering all areas of 
science, technology and medicine. 36 million abstracts from over 14,000 titles across 
4,000 publishers are available through this database including complete coverage of 
Medline titles. 
 
The quality of the studies in this review were graded using the Scottish Intercollegiate 
Grading Network 2001 (SIGN) grading system as shown in Table 2.1, based on their 
appropriate study design assessment criteria. It was decided that in order to provide 
conclusions based on a high level of evidence, non-analytical or studies based on expert 
opinion (SIGN levels three and four) will be excluded from this literature review. 
 
Table 2.1 Levels of Evidence (Scottish Intercollegiate Guidelines Network, 2001) 
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2.2.1 Search Terms 
The Cochrane Handbook suggests multiple search terms that describe the health 
condition of interest can be joined together with the Boolean „OR‟ operator, enabling 
retrieval of articles containing at least one of the search terms.  A second set of terms for 
example intervention can then be applied with the Boolean „AND‟ operator (Higgins 
and Green, 2008). To optimise the results from searches performed and minimise the 
chance of a relevant paper being missed firstly, the terms searched were mapped to their 
subject headings (MeSH). This was performed using the database being searched so that 
suitable terms recognised by that database were used. 
1. The term ovarian cancer was mapped to the subject heading Ovarian Neoplasm. 
Defined as tumours or cancer of the ovary. These neoplasms can be benign or 
malignant. They are classified according to the tissue of origin, such as the 
surface epithelium, the stromal endocrine cells, and the germ cells. 
2. The term screening was mapped to the subject heading Mass Screening. Defined 
as organized periodic procedures performed on large groups of people for the 
purpose of detecting disease. 
 
2.2.2 Study Dates to be Included 
Through a brief literature search of published literature, an extensive systematic 
literature review performed by Bell et al (1998) was found with no other more recent 
publication investigating literature evidence of ovarian cancer screening to date. 
Therefore, this systematic review will exclude studies published prior to 1998 as these 
will have already been evaluated and thus, provide the reader with findings and 
recommendations based on more recent studies. 
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2.3 Results of Systematic Literature Review 
 
2.3.1 Cochrane Library Database Search 
The Cochrane Library Database was searched on 1
st
 June 2008 using the term ovarian 
neoplasms (explode all trees) that produced 971 results and mass screening (explode all 
trees) that produced 3748 results.  Once both search terms were combined 86 results 
were found, as shown in Table 2.2. 
 Table 2.2 Cochrane Library Database Search 
 
  
 
Table 2.3 demonstrates the range of results from the resources available through the 
Cochrane Library Database. Through reviewing the title and abstract of the 86 possible 
relevant studies for inclusion 71 studies were excluded. Reasons why studies were 
excluded consisted of the study being of no relevance to this review, study being based 
on expert opinion or being published in 1998 or earlier.   
 Table 2.3 Cochrane Library Database Search Resources 
Cochrane Resources Results 
Cochrane Reviews 1 
Other Reviews 8 
Clinical Trials 53 
Methods studies 0 
Technology assessments 10 
Economic evaluations 14 
Cochrane Groups 0 
Search Terms N° of Results 
#1. Ovarian Neoplasms (Explode) 971 
#2. Mass Screening (Explode) 3748 
#3. #1 AND #2 86 
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Table 2.4 summaries the reasons why studies were excluded based on their title and 
abstract. Therefore, through the Cochrane Library Database search 15 studies were 
found to be of relevance to this review and their full text screened.   
 
 Table 2.4 Excluded studies from Cochrane Library Database search 
Reasons for studies being excluded N° of Results 
Study not relevant to this review 50 
Study based on expert opinion 3 
Study published in 1998 or earlier 14 
Study already found - duplicate 4 
  
 
 
Figure 2.1 provides an overview of the Cochrane Library Database search and what 
stages studies were excluded and why, resulting in the final 10 studies that were 
included in this review.  Each study included has been reviewed with Appendix A 
providing an analysis of each study objectives, design, SIGN grading and key findings, 
with studies organised in alphabetical order of study author. 
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Figure 2.1 Flow Diagram of Cochrane Library Database Search  
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2.3.2 SCOPUS Database Search 
The SCOPUS Database was searched on 1
st
 June 2008 using the term ovarian 
neoplasms that produced 23594 results and mass screening that produced 47407 results.  
Once both search terms were combined 527 results were found, as shown in Table 2.5. 
 
 Table 2.5 SCOPUS database search results 
 
  
 
 
 
 
Through reviewing the title and abstract of the 527 studies found through searching 
SCOPUS, 55 possible studies were found to be eligible for review. Reasons for studies 
excluded are shown in Table 2.6. 
 
  Table 2.6 Excluded studies from SCOPUS database search 
Reasons for studies being excluded N° of Results 
Study not relevant to this review 430 
Study based on expert opinion 28 
Study published in 1998 or earlier 6 
Study already found - duplicate 8 
  
 
Figure 2.2 provides an overview of the SCOPUS Database search and what stages 
studies were excluded and why, resulting in the final 23 studies that were included in 
this review.  Each study included has been reviewed, with Appendix B providing an 
analysis of each study objectives, design, SIGN grading and key findings, with studies 
organised in alphabetical order of study author. 
Search Terms N° of Results 
#1. Ovarian Neoplasms  23,594 
#2. Mass Screening  47,407 
#3. #1 AND #2 527 
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Figure 2.2 Flow Diagram of SCOPUS Database Search  
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2.4 Discussion of Systematic Literature Review  
2.4.1 Evaluation of Included Studies in Literature Review 
Through the systematic literature searches performed using the Cochrane Library and 
SCOPUS database 33 relevant studies were found and subject to a critical appraisal.  
Appendix A and B provide an overview of each study included in the review. Relevant 
studies included were performed in developed countries primarily in the United 
Kingdom and America but also include Croatia and Japan. Studies investigated various 
ovarian cancer screening techniques, compliance of screening participants and costs 
involved in offering an ovarian cancer screening service.  As shown by Figure 2.1 and 
Figure 2.2 more potential studies were found by searching SCOPUS with 527 studies in 
comparison to the Cochrane Library Database providing 86 potential studies for 
inclusion. Following screening of the abstract and full text 23 studies were found to 
fulfil all of the inclusion criteria from the SCOPUS search with the majority (20 studies 
from the 32 studies excluded) being excluded as being based on expert opinion or on a 
low level of evidence. The Cochrane Library provided 10 studies that fulfilled all of the 
inclusion criteria with just three full text studies being excluded due to no relevance to 
this review. Only one study in the Cochrane Library was found to be based on a low 
level of evidence.  
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2.4.2 Ovarian Cancer Screening Studies 
It is apparent from the literature on ovarian cancer screening that internationally 
extensive research is performed however, there is lack of consensus on who to offer 
screening to, and the most efficacious way of offering it. Through investigating the 17 
studies that aimed to determine the benefit or usefulness of ovarian cancer screening a 
wide variation in screening methods used was found.  Six different inclusion criteria 
were used in the 17 studies to decide what participants were offered screening with 
variations in their age, menopausal status and associated risk of developing ovarian 
cancer due to family history of the disease, as follows: 
1. Peri and postmenopausal women. 
2. Postmenopausal women. 
3. Postmenopausal women with raised CA125. 
4. Premenopausal and postmenopausal women. 
5. Premenopausal and postmenopausal women at high risk of developing ovarian 
cancer. 
6. Women >50yrs of age and women >25 yrs of age at high risk of developing 
ovarian cancer. 
 
As shown in Figure 2.3 the largest number of studies (six of the 17) decided to focus on 
pre and postmenopausal women at high risk of developing ovarian cancer due to family 
history of the disease. The second largest number of studies focused on all 
postmenopausal women. Other studies analysed varied in including premenopausal 
women or screening all women regardless of family history of ovarian cancer.   
  
 
44 
Figure 2.3 Population screened for ovarian cancer in studies analysed 
 
 
2.4.3 Screening Methods 
Two different screening methods were found in the 17 studies analysed. Firstly, 
screening through the use of ultrasound examination alone and secondly, using 
ultrasound imaging alongside tumour markers, typically CA125. Tables 2.7 and 2.8 
provide an overview of these two screening methods in alphabetical order of study 
author with inclusion criteria, screening method and results analysed. 
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 Table 2.7 Ovarian Cancer Screening Studies using Ultrasound alone 
 
 
 
 
 
 
Author and Year 
of Publication 
Study Inclusion Criteria Screening Method Screening Results 
(DePriest and 
DeSimone, 2003) 
University of Kentucky Programme 
 
14,469 Women 50yrs or older and Women 25yrs or 
older with family history of ovarian cancer 
 
Transvaginal 
ultrasound 
 
Sensitivity of 81% 
Specificity 98.9% 
PPV 9.4% 
NPV 99.97% 
(Fishman et al., 
2005) 
4,526 Premenopausal and postmenopausal women 
at high risk of ovarian cancer 
Transvaginal 
ultrasound 
Of the 2 primary ovarian cancers detected 
both women had normal ultrasound 
examinations 6/12 months prior to the 
diagnosis. 
(Kurjak et al., 2005) 3,201 Peri / Postmenopausal women Three- dimensional 
with power Doppler 
ultrasound 
Sensitivity of 100% 
Specificity 99.4% 
PPV 20%   NPV 100% 
(Marchetti et al., 
2002) 
4,350 Pre and Postmenopausal women Transvaginal 
Ultrasound 
Sensitivity 100% 
Specificity 99.81% 
PPV 20% 
(Van Nagell Jr. et 
al., 2007) 
25,327 Women 50yrs or older and 25yrs or older 
with a family history of ovarian cancer 
Transvaginal 
Ultrasound 
Sensitivity 85% 
Specificity 98.7% 
PPV 14.01%   NPV 99.9% 
(Tailor et al., 2003) 2500 women at increased risk of developing 
ovarian cancer 
Transvaginal 
ultrasound 
15 of the 20 cancers occurred in 
premenopausal women 
 
Sensitivity 92%   Specificity 97.8% 
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Table 2.8 Ovarian Cancer Screening Studies using Ultrasound combined with serum tumour markers 
Author and Year of 
Publication 
Study Inclusion Criteria Screening Method Screening Results 
(Bosse et al., 2006) Women at high risk of 
ovarian cancer 
Transvaginal ultrasound and CA125 Specificity of 98.7% 
Positive predictive value 10% 
(Buys et al., 2005) 28,816 Postmenopausal 
women 
Transvaginal ultrasound and CA125 PPV of Ultrasound alone 1.0% 
PPV of CA125 alone 3.7%  Ultrasound and 
CA125 23.5% 
(DePriest and DeSimone, 
2003) 
Hirosaki University 
Programme183,043Women 
30yrs or older 
Transvaginal ultrasound and serum 
tumour evaluation 
PPV 6.8% 
(Gaarenstroom et al., 
2006) 
269 women at high risk of 
ovarian cancer 
Transvaginal ultrasound and CA125 Efficacy of screening women at high risk seems 
poor as the majority of cancers were detected at 
an advanced stage 
(Jacobs et al., 1999) Postmenopausal women 
above 45yrs - Screened 
group 10,958 
Transvaginal ultrasound and CA125 Positive predictive value 20.7 
(Lacey et al., 2006) 28,460 Women with a family 
history of ovarian cancer 
Transvaginal ultrasound and CA125 Probabilities of abnormal CA125 and TVS were 
similar across the groups.  Women at higher 
family history-based risk more likely to be 
diagnosed with ovarian cancer. 
(Menon et al., 2000) 741 Postmenopausal women 
with a raised CA125 
Transvaginal ultrasound following a 
raised CA125 
Sensitivity 100%  Specificity 97% and PPV 
37.2% Using complex morphology criteria 
(Menon et al., 2005) 13,582 Postmenopausal 
women  
Transvaginal ultrasound following an 
elevated CA125 level 
Specificity 99.8%                    PPV 19% 
(Roupa et al., 2004) 120 Postmenopausal women Transvaginal ultrasound and CA125 Sensitivity 81.7%    Specificity 100% 
(Sato et al., 2000) 183,034 Premenopausal and 
Postmenopausal  
30 Second Transvaginal Ultrasound 
examination followed by tumour 
markers 
Surgery performed on 324 participants 
22 Tumours found 77% of which were classified 
as Stage 1. 
(Stirling et al., 2005) 1,110 women at increased 
risk of developing ovarian 
cancer 
Annual transvaginal ultrasound and 
CA125 
Three cancers not detected by screening – two 
stage III and one stage IV.  Sensitivity 50%  
PPV 17% 
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2.4.4 Ovarian Cancer Screening using Ultrasound Imaging alone 
Through the 6 studies found that use ultrasound alone for ovarian cancer screening 
interestingly only one does not include premenopausal women.  It is widely accepted 
that screening premenopausal women for ovarian cancer will increase the false positive 
screening rate due to benign gynaecological conditions including endometriosis, 
functional ovarian cysts and fibroids (Jacobs, 2009).  However, the clear benefit of this 
inclusion was found by Tailor et al (2003) with 15 of the 20 cancers detected in 
premenopausal women. 
 
The screening results from each study all vary in their sensitivity and specificity values 
as follows: 
o The sensitivity ranges from 81% (DePriest and DeSimone, 2003) to 100% 
(Marchetti et al., 2002; Kurjak et al., 2005). 
o The specificity ranges from 97.8% (Tailor et al., 2003) to 99.8% (Marchetti et 
al., 2002). 
o The positive predictive values range from 9.4% (DePriest and DeSimone, 2003) 
to 20% (Marchetti et al., 2002; Kurjak et al., 2005). 
 
Transvaginal ultrasound has been recognised for several years as the „gold standard‟ of 
ultrasound clinical practice, offering improved image resolution and visualisation of the 
female pelvis. Kurjak et al (2005) incorporates the use of three-dimensional ultrasound 
and power Doppler ultrasound. Three-dimensional ultrasound is not commonly used in 
routine NHS clinical practice however, this study reports a sensitivity of 100%, 
specificity of 99.4% and one of the highest positive predictive values of 20%.  
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2.4.5 Ovarian Cancer Screening Studies using Ultrasound combined with serum 
tumour markers  
The majority of the screening studies analysed incorporated the use of tumour markers 
alongside ultrasound examination with 11 studies included. Variations in study 
populations were again found with nine studies using CA125 as the biomarker of 
choice. The two other studies (DePriest and DeSimone, 2003; Sato et al., 2000) 
incorporated the use of tumour makers still being evaluated. 
 
The sensitivity and specificity values from each study are as follows: 
o The sensitivity ranges from 50% (Stirling et al., 2005) to 100% (Menon et al., 
2000) 
o The specificity ranges from 97% (Menon et al., 2000) to 100% (Roupa et al., 
2004) 
o The positive predictive values range from 10% (Bosse et al., 2006) to 37.2% 
(Menon et al., 2000) 
 
The studies analysed showed that incorporate serum tumour markers have a large 
variation in their sensitivity and positive predictive values.  The benefit of incorporating 
biomarker analysis into screening for ovarian cancer was clearly found by Buys et al 
(2005) with a positive predictive value of 1% with ultrasound alone, 3.7% with CA125 
alone and a combined positive predictive value of 23.5%.  Menon et al (2000) provides 
the most „successful‟ screening study of the 17 analysed, which involved 
postmenopausal women undergoing a transvaginal ultrasound using complex 
morphological ultrasound criteria following a raised CA125 result. The highest positive 
predictive value of all studies analysed was achieved at 37.2% with a sensitivity of 
100% and specificity of 97%.  
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2.4.6 Compliance in Ovarian Cancer Screening Studies 
It was decided that in order to investigate the impact and feasibility of an NHS based 
ovarian cancer screening programme, inclusion of studies investigating the compliance 
of a population and psychological constructs associated with screening will be included. 
Firstly, to determine rates of compliance with an ovarian cancer screening strategy, 
particularly one incorporating transvaginal ultrasound and secondly, to acknowledge the 
psychological distress participants in a screening study may experience and what impact 
that may have.   
 
Through analysis of the screening studies performed with variations in screening 
methods used it is important to note that annual screening seems inadequate for early 
ovarian cancer detection. Firstly, Stirling et al (2005) concluded that annual surveillance 
with ultrasound and CA125 is ineffective in detecting tumours at a sufficiently early 
stage to influence prognosis with three cancers (two Stage III and one Stage IV) not 
being detected by screening and presenting in the interim screening period.  Secondly, 
Gaarenstroom et al (2006) found the majority of cancers were detected at an advanced 
stage. Thirdly, Fishman et al (2005) detected two primary ovarian cancers both of which 
had normal ultrasound examinations 6/12 months prior to the diagnosis. This therefore, 
suggests that the disease is often aggressive and monitoring of ovarian appearance and 
biomarker analysis is required more frequently than every 12 months.  It is accepted as 
current imaging practice that ultrasound examinations incorporate a transvaginal scan 
due to the improvement of image quality achieved through high resolution probes in 
close proximity to the ovaries. However, if this intensive screening is required Drescher 
et al (2004) found that compliance of average and intermediate risk women to an 
ovarian cancer screening protocol requiring semi-annual screening diminished rapidly 
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and a screening method incorporating transvaginal ultrasound may be too intensive for 
use in this population. Similar low compliance of women returning for repeat screening 
was found by Andrykowski et al (2007) with over 25% of the sample population not 
returning for repeat ultrasound screening within 24 months of their baseline 
examination. In comparison, Pavlik et al (2000) found high levels of continuation 
through annual ultrasound screening with 96% of women returning for visits within two 
years, indicating that women take ovarian cancer disease seriously and it is of 
consequence to them through continuing with screening.  Hensley et al (2003) found 
that the perception of ovarian cancer risk and risk-related anxiety was higher in 
premenopausal women along with increased false-positive results in comparison to 
postmenopausal women. However, Tailor et al (2003) highlights the need for screening 
premenopausal women as 15 of the 20 cancers detected in this study were in this 
population.   
 
It is important to address the efficacy of subjecting asymptomatic participants to 
screening, particularly involving transvaginal ultrasound. Salsman et al (2004) found 
that nearly all women both in the healthy comparison group and those already involved 
in an ovarian cancer screening trial endorsed positive beliefs in the ability of 
transvaginal ultrasound to detect ovarian cancer and the curability of ovarian cancer if 
detected early.  More importantly to this literature review, the groups did not differ 
regarding beliefs concerning the efficacy of transvaginal ultrasound screening for 
ovarian cancer.  Salsman et al (2004) found 88.3% of women invited to undergo 
screening provided informed consent. Those who declined screening cited reasons as 
too busy or too stressed.  This aspect of stress and cancer worry was addressed by 
Andersen et al (2007) who found that ovarian cancer screening does not have significant 
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negative effects on participants, at least when they do not receive abnormal results. For 
those who receive abnormal results, screening may have long-term effects and increase 
worry about cancer risk.  A previous study by Andersen et al (2002) highlights that most 
women over-estimated their risk of developing ovarian cancer with those at risk of the 
disease due to family history experiencing particularly worry and anxiety.  Their study 
also found that a significant percentage of women at high risk of developing ovarian 
cancer fail to get recommended screening.   
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2.5 Conclusion of Systematic Literature Review 
 
The conclusions and recommendations made in this review are based on the best 
available evidence taken only from well conducted randomised control trials, case 
control or cohort studies. Non analytic studies and expert opinion publications were 
excluded. 
 
Bell et al (1998) performed a systematic literature review to provide the HTA 
programme with an overview of the results of research evaluating screening for ovarian 
cancer.  Similar findings were observed in studies performed prior to 1998 as in this 
review, with wide variations in inclusion criteria and modalities used for screening 
study participants. Bell et al (1998) concluded that uncontrolled screening studies could 
not provide reliable evidence concerning the effect of ovarian cancer screening on 
health outcomes such as mortality and quality of life. It is clear that there is a level of 
uncertainty as to which women to offer screening to from studies analysed in this 
review from 1998 to 2008. However, even though there is variability in screening 
inclusion criteria used, this review suggests that ovarian cancer is often aggressive and 
monitoring of ovarian appearance and biomarker analysis is required more frequently 
than every 12 months. Annual screening was found to be inadequate for early cancer 
detection by Stirling et al (2005) and Gaarenstroom et al (2006) who reported that the 
majority of cancers were either detected at an advanced stage or presented in the interim 
screening period.  Fishman et al (2005) detected two primary ovarian cancers both of 
which had normal ultrasound examinations six months prior to the diagnosis.  It is 
important to also note that Andrykowski et al (2007) and Drescher et al (2004) found 
that participant compliance was often low when screening within a 12 month period 
particularly when involving transvaginal ultrasound examinations. This aspect of 
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participant compliance to a screening protocol raised in this review is important, as 
assuming the effectiveness of cancer screening is predicted on timely screening then 
only through a high rate of participation can early ovarian cancer detection be proposed.  
 
As previously mentioned it is widely accepted that screening premenopausal women for 
ovarian cancer will increase the false positive screening rate due to benign 
gynaecological conditions including endometriosis, functional ovarian cysts and 
fibroids (Jacobs, 2009).  However, the clear benefit of this inclusion was found in Tailor 
et al (2003) study with 15 of the 20 cancers detected in premenopausal women.  This 
has an implication for ovarian cancer screening in the NHS setting as potentially more 
women may need to be offered screening rather than focusing entirely on 
postmenopausal women.   
 
The most successful screening study of the 17 analysed was performed by Menon et al 
(2000) and agrees with literature evidence that ovarian cancer screening involving 
multimodal screening has superior specificity and positive predictive value. Menon et al 
(2000) focused on postmenopausal women undergoing a transvaginal ultrasound using 
complex morphological ultrasound criteria following a raised CA125 result. This 
screening method resulted in the highest positive predictive value of all studies analysed 
at 37.2% with a sensitivity of 100% and specificity of 97%.  However, it is important to 
remember the possible low compliance of women to a screening protocol that involves 
semi-annual screening with transvaginal ultrasound should CA125 levels indicate more 
frequent ultrasound examinations are necessary (Drescher et al., 2004).  
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2.6 Recommendations from Systematic Literature Review 
 
Based on this systematic literature review the main recommendation that must be made 
particularly when the NHS National Screening Committee is due to evaluate their 
opinion on ovarian cancer screening, is that currently there is no agreed method of 
screening or inclusion criteria being adhered to. This aspect of screening in the NHS 
setting must be decided upon with justification based on clinical evidence as screening 
methods and inclusion criteria used will have varying cost implications. 
 
It is clear that ultrasound and CA125 both have limitations in their sensitivity and 
specificity of diagnosing ovarian cancer and therefore, further work must be 
recommended in these areas as both are required in clinical practice to reach a diagnosis 
and screening for early detection of the disease.  The benefit of incorporating biomarker 
analysis into screening for ovarian cancer was clearly found by Buys et al (2005) with a 
positive predictive value of 1% with ultrasound alone, 3.7% with CA125 alone and a 
combined positive predictive value of 23.5%.  Biomarker research may provide new and 
more clinically useful markers to aid practitioners in the early detection of ovarian 
cancer and more specific to stage at diagnosis. Further research into imaging 
particularly in the field of ultrasound due to this modality being the first line 
investigation is suggested.  Complex morphological ultrasound criteria as used by 
Menon et al (2000) achieved the highest positive predictive value of all studies analysed 
and could therefore, provide a useful and robust method of deciding the likelihood of 
malignancy in a systematic way for all practitioners performing gynaecological 
ultrasound. An example of a transvaginal ultrasound classification algorithm as used in 
UKFOCSS is provided in Appendix G and is particularly appropriate for premenopausal 
women in whom functional cysts are common but a risk of developing ovarian cancer 
still exists. (Tailor et al, 2003). 
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Kurjak et al (2005) incorporates the use of three-dimensional ultrasound and power 
Doppler ultrasound not commonly used in routine NHS clinical practice.  However, this 
study reports a sensitivity of 100%, specificity of 99.4% and one of the highest positive 
predictive values of 20% suggesting a possible very useful advancement in the field of 
imaging and ultrasound characterisation of ovarian lesions. This literature review 
highlights the need for screening more frequently than on an annual basis, however, it is 
important to note the low compliance found by Andrykowski et al (2007) and Drescher 
et al (2004) to a frequent screening protocol particularly one using transvaginal 
ultrasound. Therefore, research into a more sensitive and clinically useful biomarkers 
present in blood would provide a cost-effective and possibly more acceptable method of 
screening during the interim period of annual transvaginal ultrasound examinations. 
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3 RETROSPECTIVE STUDY OF 
CONFIRMED AND SUSPECTED 
OVARIAN CANCER CASES 
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3.1 Introduction 
 
In order to investigate the impact of introducing ovarian cancer screening and to gain an 
insight into the clinical problem that ovarian cancer presents at a local level, a 
retrospective study was performed at Milton Keynes Hospital NHS Foundation Trust.  
Ethical approval was applied for and granted from Milton Keynes Research Ethics 
Committee on 14
th
 July 2008 (REC reference 08/H0603/14).   
 
Two searches were performed differing in their objectives: 
1. Perform a retrospective study of patients diagnosed with ovarian cancer at 
Milton Keynes Hospital over a five year timescale from 2004 to 2009 regardless 
of presentation or method of diagnosis, to establish the stage at diagnosis, age 
and family history of the disease.  
2. Investigate the role and diagnostic accuracy of imaging when suspecting ovarian 
pathology to establish how many cases with suspected malignancy or pathology 
undetermined through imaging alone resulted in benign pathology. 
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3.2 Design of Retrospective Studies 
 
The first retrospective study aimed to find the maximum number of patients diagnosed 
with ovarian cancer at Milton Keynes Hospital through implementing two search 
methods. Firstly, all patients referred for treatment following a diagnosis of ovarian 
cancer are seen by a Consultant Oncologist at Northampton Hospital, contact was made 
for a list of patients referred from 2004 to 2009 and the National Cancer Registry 
searched.  Secondly, in order to find those patients not given treatment as palliative care 
may have been appropriate or follow-up care provided in a different region, a keyword 
search of medical reports held on the radiology database used at Milton Keynes 
Hospital was performed to establish a diagnosis.  Figure 3.1 provides an overview of 
how the total number of patients diagnosed with ovarian cancer at Milton Keynes 
Hospital was found.  
 
 
Patient with suspected ovarian malignancy on imaging 
 
Surgical removal / biopsy for confirmation of disease 
 
     Referral to a Consultant Oncologist at                  Palliative Care  
      Northampton Hospital for treatment  
                                 
Total number of patients with ovarian cancer  
diagnosed at Milton Keynes Hospital 
 Figure 3.1 Method of First Retrospective Study 
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Once all patients diagnosed at Milton Keynes Hospital with ovarian cancer were found 
the following information was collected through examining their medical notes and 
incorporating data held on the radiology or histology database when required: 
o Age at diagnosis 
o Menopausal status   
o Stage of ovarian cancer – FIGO classification of disease 
o Presenting symptoms and diagnostic findings 
o CA125 level 
o Documented medical history or family history of cancer 
 
As detection of ovarian cancer involves an imaging modality alongside biomarker 
analysis, a second retrospective study was performed in order to investigate the 
challenges that imaging face in the characterisation of ovarian pathology.  The aim of 
this second retrospective study was to establish how many cases with suspected 
malignancy through imaging alone resulted in benign pathology (false-positive results) 
and establish the outcome of cases with complex ovarian pathology unable to be 
characterised as benign on first-line imaging. This aspect of imaging diagnostic 
accuracy is key when investigating the impact of ovarian cancer screening, as a 
modality that offers a high sensitivity and specificity level is vital in detecting small-
volume disease states and accurately identify individuals without disease (Teneriello 
and Park, 1995). 
 
The current radiology information system at Milton Keynes Hospital has been in use for 
18 months and therefore, the search was performed over this timescale incorporating all 
female patients of any age and of any imaging modality.  Figure 3.2 provides an 
overview of the second retrospective study design. 
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As both Consultant Radiologists and Reporting Sonographers perform imaging 
examinations in the field of general medical and gynaecology ultrasound there is a 
variation in how medical reports are structured and described by the practitioner.  
Therefore, to maximise the number of patients found in this search several Radiologists 
and Reporting Sonographers were approached to find how they describe and report on 
ovarian pathology to develop a list of search terms used. Search terms decided upon 
were as follows and all were used with the Boolean OR operator for the database 
search: 
o Ovarian mass Ovarian malignancy 
o Ovarian carcinoma Ovarian tumour 
o Complex mass Complex cyst 
o Adnexal mass Adnexal cyst 
 
Cases eligible for inclusion in this second study were as follows: 
o Any case where ovarian pathology has been detected but not able to be 
characterised by the practitioner as benign using one imaging modality. 
o Any case where ovarian pathology has been detected and incorrectly 
characterised as benign using one imaging modality (false-negative result). 
o Any case where surgical intervention was required for histology analysis of 
ovarian tumour resulting in a final diagnosis of a benign nature (false-positive 
result). 
Figure 3.2 Method of Second Retrospective Study 
Radiology database search 
 
Each patient investigated for eligibility 
(Female and suspected to have malignant ovarian pathology on imaging) 
 
Final outcome investigated through radiology database or histology database 
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3.3 Results of First Retrospective Study 
 
A total of 75 cases of ovarian cancer were found through implementing the two search 
methods described with all sets of medical notes found and examined. Interestingly all 
medical notes had excellent and detailed documentation meaning that all of the key 
information set out to gather was achievable. Information from Milton Keynes Hospital 
radiology database and histology reports were used to confirm the diagnosis or provide 
additional information to cases analysed. 
3.3.1 Age at Diagnosis 
The age range of patients diagnosed with ovarian cancer was found to be from 30 to 87 
years of age. The median age calculated was 59.  A dispersion of age range was found 
through calculating the first quartile and third quartile equalling 53 to 70 years of age. 
Figure 3.3 provides a box-plot of age at diagnosis and FIGO classification of disease, as 
shown; both young and older women were diagnosed in all four stages of disease.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 FIGO Classification of Disease and Age at Diagnosis 
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A statistically significant difference was found between each group using the ANOVA 
test, resulting in a p-value of 0.000554. These findings suggest that although each stage 
does have a wide age range, older women tend to have more advanced disease (Stage III 
or IV) at time of diagnosis with younger women more likely to be diagnosed with early 
disease (Stage I or II). 
 
3.3.2 Menopausal Status 
Through reviewing medical notes, reasons why patients were referred for imaging and 
symptoms experienced, the menopausal status was recorded resulting in the majority of 
women (77%) diagnosed with ovarian cancer found to be postmenopausal.  However, 
from the 75 cases found, 17 patients were premenopausal and often referred due to 
irregular vaginal bleeding and pain. 
Table 3.1 Menopausal Status of Ovarian Cancer Cases 
3.3.3 Stage of Ovarian Cancer 
Through reviewing the medical notes and post-surgical oncology review once the stage 
of ovarian disease was decided, each case was documented. This retrospective analysis 
found the largest group of patients (23 of the 75 cases) were found to have advanced 
FIGO Stage IV disease at time of diagnosis. Therefore, these women were found to 
have ovarian cancer along with distant metastatic disease. The second largest group of 
patients (20 of the 75) were found to have early FIGO Stage I disease at time of 
diagnosis.  Figure 3.4 demonstrates the variability in FIGO classification of disease that 
patients presented with at time of diagnosis at Milton Keynes Hospital. 
 
Number of Cases Menopausal Status 
17 Premenopausal 
58 Postmenopausal 
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3.3.4 Presenting Symptoms 
As previously mentioned the symptoms of ovarian cancer are often vague and difficult 
to recognise particularly in the early stages of the disease. Similar presenting symptoms 
from the 75 cases were found with 57% of the cases reviewed experiencing at least two 
or more of these symptoms: 
o Abdominal or pelvic pain / distension 
o Change in bowel habit 
o Weight loss 
o Abnormal vaginal bleeding 
o Urinary symptoms / frequency of micturition 
The most common symptom found was abdominal or pelvic pain often with distension, 
with 80% of the cases reviewed having this symptom documented.  From evaluating the 
medical notes it was clear that due to the variability in presentation and often non-
specific symptoms, patients with underlying ovarian cancer were often initially referred 
Figure 3.4 FIGO Classification of disease and number of cases 
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to clinicians in gastrointestinal medicine in cases 17, 39, 42 and 49 as these patients 
experienced change in bowel habit with weight loss and often abdominal pains, 
meaning the referring general practitioner was suspecting bowel pathology rather than 
ovarian disease (Appendix D). Other key cases include: 
o Case 38 that presented with a pleural effusion on a medical ward under the chest 
physicians who found adenocarcinoma in the fluid drained and therefore, 
requested imaging resulting in a final diagnosis of advanced Stage IV ovarian 
cancer.  
o Case 29 is of particular interest as this patient was experiencing pelvic pain and 
found to have FIGO Stage III disease on surgical laparoscopy. However, just 
four months prior had a normal CT examination. This case provides a key 
example of how quickly ovarian cancer can develop and spread. 
 
3.3.5 Diagnostic Findings 
The majority of cases (93%) in this retrospective study had ovarian pathology first 
diagnosed by an ultrasound examination. This modality is routinely used as first line 
imaging for gynaecologists and general practitioners suspecting gynaecological 
pathology at Milton Keynes Hospital.  The size of the ovaries and morphology can be 
assessed for the presence of cysts, cyst septae, solid areas and solid papillations. An 
abnormal ultrasound is classified as cysts above 5cm in diameter, multiple cysts or all 
complex morphology (non-uniform echogenicity). Following an ultrasound examination 
demonstrating a pelvic or abdominal complex cyst or mass, all patients underwent a CT 
examination to aid in staging the disease. Several patients also had an MRI examination 
for further investigation prior to surgical intervention. 97% of ovarian cancer cases in 
this retrospective study had a pelvic or abdominal mass / cyst diagnosed by imaging 
prior to surgical intervention.  
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Cases 10 and 48 were found to have peritoneal metastatic disease and omental 
thickening without a definite ovarian tumour visualised by imaging. In all other 73 cases 
a complex mass / tumour or enlarged abnormal ovaries were visualised with tumour 
ranging from 6cm up to 16cm in size. Other diagnostic features also detected on 
imaging included: 
 Omental spread / peritoneal deposits 
 Liver / lung metastasis  
 Ascites / pleural effusion 
 Bowel / uterus / cervical / fallopian tube involvement 
 Lymphadenopathy 
 Deposits under the diaphragm 
 
Case 63 provides a key finding from this retrospective study as a false negative result 
based on ultrasound examination in a patient who presented with a palpable pelvic mass 
of unknown cause was found. This was reported as an enlarged fibroid uterus on 
ultrasound, however, a later CT and MRI examination confirmed FIGO Stage III 
ovarian cancer with a normal sized uterus. This case is of vital importance in 
highlighting how operator dependant ultrasound examination is, particularly as in this 
case a transvaginal scan was not performed. 
 
3.3.6 CA125 Analysis 
A wide variation in CA125 values was found through reviewing each case on the 
Winpath database at Milton Keynes Hospital with a range of 7U/ml to 5000U/ml.  A 
CA125 of above 35U/ml is normally accepted as elevated in premenopausal women and 
above 30U/ml in postmenopausal women.  Interestingly, six patients diagnosed with 
ovarian cancer were found to have CA125 values within the normal range: 
  
 
66 
  Figure 3.5 Boxplot of FIGO Classification of Disease and CA125 
o Cases 12,47 and 50 were diagnosed with FIGO Stage I disease. 
o Case 16 was found to have FIGO Stage II disease with a CA125 value of just 
11U/ml and also a family history of mother and sister previously diagnosed with 
ovarian cancer.   
o Cases 29 and 58 are perhaps the most interesting and concerning finding of this 
retrospective study as advanced FIGO Stage III and IV disease was diagnosed, 
with normal range CA125 levels 
 
In order to provide an overview of CA125 levels in relation to FIGO stage at diagnosis, 
a boxplot has been used as shown in Figure 3.5.  
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Key findings from Figure 3.5 are as follows: 
1. Cases of ovarian cancer with a CA125 within the normal range were found in all 
four FIGO stages of disease. 
2. Several cases had a very high (>4000U/ml) CA125 regardless of FIGO stage at 
diagnosis. 
3. A statistically significant difference was found between each group using the 
ANOVA test, resulting in a p-value of 0.003542. These findings therefore, 
indicate that there is a gradual increase in CA125 with advancing FIGO 
classification of disease. 
 
3.3.7 Documented History of Cancer 
A low incidence of cancer history from the 75 cases was found with six cases having a 
documented history in their medical records.   
o Cases 10, 35, 51 and 65 had a documented family history of breast cancer with 
one patient being a BRCA1 gene carrier. Interestingly, three of these cases had 
advanced (Stage IV) ovarian cancer at time of diagnosis. 
o Case 16 had family history of ovarian cancer with mother and sister already 
diagnosed with the disease. 
o Case 18 had a history of cervical cancer.  
This may therefore, suggest an incidence of 6.7% familial ovarian cancer rather than 
sporadic disease (5 cases from the 75 found). 
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3.4 Results of Second Retrospective Study 
 
A search performed using the radiology database at Milton Keynes Hospital provided 
169 patients with at least one of the search terms, as described in Chapter 3.2, used in 
their imaging reports. Through examining all of the imaging reports highlighted in this 
search, 35 cases suspicious of ovarian malignancy or unable to be classified as benign 
were found, all of which resulted in either further imaging or histology analysis to 
confirm benign ovarian pathology following surgery. 
 
3.4.1 Age Range 
A wide age range was found from 16 to 83 years of age with the majority of patients 
(89%) being premenopausal.  
 
3.4.2 Imaging Findings 
In the 35 cases analysed all patients had a complex pelvic mass that often involved solid 
components and meant that through initial imaging alone either the Radiologist or 
Reporting Sonographer were unable to characterise the pathology as benign.  The size 
of abdominal or pelvic masses ranged from 5cm up to 32cm.  89% of the cases found 
involved ultrasound imaging with the remaining 11% involving CT or MRI being 
unable to characterise the mass as benign on first examination. Similar imaging findings 
were documented as follows: 
 Ovarian mass with cystic and solid components. 
 Complex ovarian cyst with thick internal septations and solid areas. 
 Multilocular cystic mass. 
 Enlarged ovary with abnormal lesions and wall irregularity. 
 Free pelvic fluid. 
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Figure 3.6 How a diagnosis of benign pathology was reached 
3.4.3 Outcome of Cases 
The outcome of each case was investigated through searching the radiology database 
reports for follow-up or histology reports following surgical intervention. Each case 
found either involved further imaging examinations or surgical removal of the mass for 
histology analysis in order to confirm non-malignancy. 
 
Figure 3.6 provides an overview of how each case reached a diagnosis of benign 
pathology.  Of the 35 cases investigated, four methods were used, histology analysis 
following surgical intervention, MRI, CT or further ultrasound imaging. The largest 
number of cases either resulted in histology analysis following surgical removal or MRI 
imaging to establish a diagnosis.  A large percentage of patients (40%) still required 
surgical intervention when imaging suggested ovarian pathology of unknown nature.  
60% of patients required further imaging through a different modality most commonly 
MRI or a further ultrasound at a later date for reassessment of the ovaries decided by the 
clinician. 
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Non-malignant gynaecologic pathology was diagnosed in 34 of the 35 cases 
investigated with the outcome of each case recorded in Table 3.2. A single case of 
suspected ovarian malignancy on imaging resulted in bowel pathology following 
surgical intervention and histology analysis. 
 
   Table 3.2 Outcome of suspected ovarian pathology diagnosis 
Outcome Number of Cases 
Benign simple ovarian cyst or 
further imaging demonstrates normal ovaries 
11 
Endometrioma 7 
Dermoid Cyst 6 
Uterine fibroid 4 
Haemorrhagic cyst 3 
Ovarian fibroma 1 
Pelvic abscess 1 
Fluid collection 1 
 
As shown in the largest number of cases the outcome was benign simple ovarian cysts 
or following further imaging the cyst had resolved meaning ultrasound or MRI/CT 
demonstrated normal ovaries.  Other cases involved gynaecological conditions of 
endometriosis, dermoid cysts, uterine fibroids, haemorrhagic cysts or an ovarian 
fibroma. Two cases were found to have loculated fluid collections or pelvic abscess 
following further imaging. 
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3.5 Discussion of Retrospective Studies 
Through the two retrospective studies performed at Milton Keynes Hospital NHS 
Foundation Trust, an insight has been provided into the clinical problem that ovarian 
cancer and benign pathology presents at a local level. A total of 75 cases of ovarian 
cancer were found over a five year period through applying the search methods 
described with variations in age, menopausal status, symptoms experienced and FIGO 
stage at diagnosis found.   
 
As five-year survival rates are related to the age at which the disease is diagnosed with 
women under the age of 50 years likely to be diagnosed with local disease and women 
over 65 years being more likely to have distant metastases, the stage at diagnosis is vital 
for treatment management and survival. The first retrospective study found that 81% of 
women diagnosed with ovarian cancer were above the age of 50 with 77% of women 
being postmenopausal. This finding agrees with Cancer Research UK (2009) who state 
that over 80% of ovarian cancer cases are diagnosed in women over 50yrs of age as 
seen in Figure 1.3.  17 women were found to be premenopausal with the majority 
referred due to irregular vaginal bleeding and pelvic pain.  Figure 1.5 demonstrates the 
difference from women aged 15-39 having a five-year survival rate of nearly 70% to 
that of 12% survival if diagnosed between 80-89 years of age.  Both FIGO and Menon 
and Jacobs (2002) find that approximately 25% of patients present with Stage I or Stage 
II disease.  However, this retrospective study found 44% of all cases at Milton Keynes 
Hospital were diagnosed earlier than progressing to Stage III as shown in Figure 3.4.  
Reasons for this were not apparent from this retrospective study as the clinical 
presentation and symptoms experienced were similar across all stages of ovarian cancer. 
It potentially could be due to the raised awareness of the disease with more women 
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seeking advice when symptoms initially present and general practitioners referring for 
more diagnostic examinations when symptoms experienced are vague.  The largest 
group of cases were diagnosed with advanced FIGO Stage IV disease (31%) 
interestingly followed by Stage I disease (27%). This suggests that many cases will be 
diagnosed with advanced disease involving distant metastases as suggested by Rufford 
et al (2007) due to often vague symptoms experienced, however, many cases were 
found to have tumour concentrated only in the ovaries.  The most common symptom 
found was abdominal or pelvic pain often with distension, with 80% of the cases 
reviewed having this symptom documented.  Cases 17, 39, 42 and 49 highlight the 
problems of vague symptoms as due to changes in bowel habit with weight loss, bowel 
pathology was suspected by referring general practitioners rather than ovarian disease. 
Case 29 is of particular interest as FIGO Stage III disease was detected on surgical 
laparoscopy, however, just four months prior had a normal CT examination. This case 
provides a key example of how quickly ovarian cancer can develop and spread. 
 
Based on current literature (Jacobs, 2009) a reduction in the specificity of imaging 
diagnosis and false-positive rates are higher in premenopausal women due to benign 
functional cysts, uterine fibroids and cases of endometriosis in this population. This 
aspect of imaging and implications for screening premenopausal women is highlighted 
by the second retrospective study with 35 cases found all resulting in further imaging or 
histology analysis to reach a diagnosis of benign pathology. A single false positive case 
was found in which an enlarged fibroid uterus was diagnosed by ultrasound and further 
imaging prior to surgical intervention found FIGO Stage III ovarian cancer.  Therefore, 
in relation to ovarian cancer screening through ultrasound, gynaecologists and those 
performing ultrasound examinations must be aware of these limitations. However, it is 
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important to mention that in this case a transvaginal scan was not performed. CA125 is 
often limited in predicting how advanced ovarian disease is at time of diagnosis and 
often will not detect the disease at all regardless of FIGO stage based on this 
retrospective study. Six patients diagnosed with ovarian cancer were found to have a 
CA125 within the normal range. A statistically significant difference was found 
between each FIGO stage and CA125 values recorded indicating that older women tend 
to have more advanced disease at time of diagnosis. 
 
3.5.1 Strengths and Limitations of Retrospective Studies performed  
Through deciding on a study design prior to any searches being performed the inclusion 
criteria was clear with the maximum number of patients found through several routes 
used. The objectives decided upon were achieved for each of the retrospective studies 
performed with additional information gathered through access to the radiology and 
histology database meaning if information was missing from the medical notes this 
could be accumulated and confirmed through other sources.  Statistical advice was 
requested from a senior research officer meaning any statistically significant differences 
in information collected could be confirmed and highlighted. The first study was carried 
out over a five year timescale meaning a large amount of information was analysed. The 
second study could only be carried out over an 18 month timescale due to a new 
radiology system being in place, meaning fewer patients were found and included 
however, still provides an investigation of 35 cases. 
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3.5.2 Conclusion of Retrospective Studies 
This retrospective study shows that ovarian cancer affects a wide age range with many 
women having no family history of breast or ovarian cancer. Many women were found 
to have ovarian cancer at FIGO Stage I or II however, the largest group of women were 
found to have metastatic disease at time of diagnosis. One of the most interesting 
findings from this audit in terms of symptoms experienced is the 80% of cases found 
had abdominal or pelvic pains often with distension. However, the often varied 
symptoms experienced by women with this disease reflect the known difficulty in 
detecting the cancer in its early stages. The vague abdominal pains or changes in bowel 
habit can often be similar to irritable bowel symptoms or other non-gynaecological 
conditions and therefore, the ovarian tumour can potentially go undiagnosed for some 
time.  Key findings relevant to screening for ovarian cancer are firstly, the biomarker 
CA125 used in both clinical practice and the majority of screening studies analysed in 
chapter two has limitations. Six patients with the disease were found to have a CA125 
level in the normal range, one of which had advanced FIGO Stage IV disease, indicating 
the sensitivity limitations CA125 has with detecting ovarian cancer even at advanced 
stages.  Secondly, the majority of patients in this study had no family history of breast 
or ovarian cancer and an age range from 30 to 87 years old, meaning that 
premenopausal women are at risk of developing ovarian cancer as well as 
postmenopausal women. This finding agrees with Tailor et al (2003) who found a large 
proportion of ovarian cancers (15 of the 20) in premenopausal women.  Finally, Case 29 
provides a key example of how quickly ovarian cancer can develop and spread with 
FIGO Stage III disease detected on surgical laparoscopy, however, just four months 
prior had a normal CT examination. This case indicates that annual screening for 
ovarian cancer is not suitable and either examination of the ovaries through imaging or 
biomarker analysis within a 12 month time period is vital for early diagnosis. 
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4 COST ANALYSIS OF OVARIAN 
CANCER SCREENING 
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4.1 Cost Analysis Introduction 
It is estimated that the treatment of cancer accounts for 5 per cent of all NHS 
expenditure. £3.4 billion was spent on cancer services in 2003/04, £3.8 billion in 
2004/05 and £4.3 billion was spent in 2005/06, demonstrating an increase of 12% per 
year. In total, approximately £4.35 billion was spent on cancer services in 2006/07 
(Cancer Research UK, 2009). 
 
The cost of offering screening is of key importance when proposing or justifying the 
National Health Service in offering such a programme. As suggested by Lux et al 
(2005) early cancer detection can prove to be a psychological strain for women at risk 
and a financial burden to the health system but it is a less invasive option than 
prophylactic surgery.  Through the literature review no study was found investigating 
the costs associated with ovarian cancer screening alone. Miller et al (2001) investigated 
the health related quality of life and cost-effectiveness in the prostate, lung, colon and 
ovary trial (PLCO trial).  This study provides an insight into the framework for cost-
effectiveness and health related quality of life measurements. Figure 4.1 provides the 
framework used to facilitate decisions on the measurements and timing that may be 
required with each numbered node indicating a point in the screening, diagnosis, 
treatment, follow-up and final endpoint process when health-related quality of life 
changes and cost expenditures occur. 
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 Figure 4.1 Framework for cost-effectiveness and health-related quality of life measurements (Miller 
et al, 2001) 
 
Currently the PLCO trial is still ongoing and therefore, costs associated with the 
screening offered are still being determined. However, Figure 4.1 demonstrates that 
assessing quality of life and costs within a large screening trial is not a simple exercise.  
Miller et al (2001) provides an explanation of each numbered node and costs associated 
with screening as found in Table 4.1. 
 
 
 
 
 
*or lung, colon, rectum or ovarian cancer in the PLCO trial 
Diagnostic Tests (6) 
Cancer (7) False Positive (8) 
Treatment (9) 
Interval Cancer (11) 
Follow-up (10) 
Rescreen (15) 
Death 
from  
prostate*  
cancer 
 (19) 
Death 
from  
Other 
causes 
 (21) 
Negative 
(16) 
Positive 
(17) 
Follow-up 
(18) 
Follow-up 
(14) 
Treatment (13) 
Death 
from  
Other 
causes 
 (22) 
Death 
from  
prostate* 
cancer 
 (20) 
Cancer (12) 
Positive (4) 
Negative (5) 
Eligible Participants (1) 
Screening (2) 
Randomisation 
Usual care (3) 
etc               etc 
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Table 4.1 Explanation of each numbered node (Miller et al, 2001) 
1 There is a cost associated with identifying participants eligible for 
screening. 
2 Costs associated with the screening tests are important, as they may be the 
major cost of the screening process. 
3 Costs associated with usual care including physician‟s visits for symptoms 
associated with cancer and any diagnostic tests. 
4/5 There are costs associated with notifying screen-test results. 
6/8 Distinguishing true from false positives and managing false-positives 
require special study, as these may not be under the control of the screening 
centre with implications for insurance. 
7/9/10 The costs of treating true-positives will vary by stage. 
11/12/13/
14 
The costs of identifying, treating and managing interval and non-screen-
detected cancers should be the same by stage, age and centre as for the 
general population. 
15/16/17 Re-screening costs will be similar to the initial screening, although they 
involve costs associated with ensuring compliance. 
18 Associated costs of follow-up of the usual care group. 
19/20 Associated costs with terminal illness from fatal cancers may be incurred 
earlier in life in the usual care group than the study group. 
21/22 Associated costs for caring for people dying of other causes will also 
require study. 
 
A later publication by Lafata et al (2004) identified 1,087 participants in the same 
PLCO screening trial with the aim of determining the medical and non-medical costs 
associated with false-positive prostate, lung, colorectal and ovarian cancer screens.  
43% of the sample incurred at least one false-positive cancer screen with the majority of 
these patients (83%) receiving follow-up care. Significantly higher medical care 
expenditures were found in the year following screening among those with a false-
positive screen. Transvaginal ultrasound alongside CA125 was used as the screening 
method in the PLCO trial resulting in a false positive result of 3.2% with transvaginal 
ultrasound and 0.5% with CA125 in this sample analysed. The most frequently used 
follow-up tests for women with a false-positive ovarian cancer screen were repeat 
CA125 (55.6%) and transvaginal ultrasound (44.4%). 
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4.2 NHS Based Cancer Screening Programmes 
There are three cancer screening programmes currently offered in the National Health 
Service, breast, cervical and bowel.  
 
4.2.1 Breast Cancer Screening 
The NHS Breast Screening Programme was setup in 1988 and provides free breast 
screening every three years to all women in the UK aged 50 to 70 years of age. This age 
range will be extended to 47 to 73 years of age by 2012. Breast cancer screening was 
implemented following Forrest recommendations that mammography can lead to 
prolongation of life for women aged 50 and over with convincing evidence that based 
on clinical grounds a change in UK policy was required. Key figures at 31
st
 March 
2008, most recently available, (The Health and Social Care Information Centre, 2009): 
 
o Among women aged 53-64 over three-quarters (76.6%) had been screened at 
least once in the previous three years. 
o Over 2.2 million women (aged 45 and over) were invited for screening with over 
1.7 million women being screened. 
o 14,100 cases of cancer were diagnosed in women aged 45 years and over. Of all 
cancers diagnosed 11,110 (78.7%) were invasive and of these 5,814 (52.3%) 
were 15mm or less which could have not been detected by hand. 
o In England the budget for the breast screening programme is now estimated to 
be approximately £75 million. This works out at around £37.50 per woman 
invited or £45.50 per woman screened. 
o The breast screening programme is to develop further extending the age range 
from 47 to 73 years of age over time. 
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4.2.2 Cervical Cancer Screening 
Cervical screening is a method of preventing cancer by detecting and treating early 
abnormalities which, if left untreated could lead to cancer of the cervix. The study aims 
to reduce the incidence of invasive cervical cancer and its associated mortality rates. All 
women aged 25 to 64 are eligible for a free cervical screening test every three to five 
years depending on their age.  Key figures at 31
st
 March 2008, most recently available, 
(The Information Centre for Health and Social Care, 2008): 
o 4.18 million women were invited for screening with 3.4 million women being 
screened in 2007-08. 
o Cervical screening, including the cost of treating cervical abnormalities, has 
been estimated to cost around £157 million a year in England. Primary Care 
Trusts commission cervical screening from the overall allocation they receive 
from the Department of Health.  
 
4.2.3 Bowel Cancer Screening 
Bowel cancer screening aims to detect bowel cancer at an early stage in asymptomatic 
people when treatment is more likely to be effective. The NHS bowel cancer screening 
programme offers screening to all men and women aged 60-69. Key figures at 31
st
 
March 2008, most recently available, (NHS Cancer Screening Programmes, 2008): 
o A pilot study was performed with 478,250 residents of pilot areas invited to take 
part with an uptake of 56.8%.  552 cancers were detected by screening. 
o Following the pilot, NHS bowel cancer screening was introduced in July 2006. 
o In 2006-07 the cost of the bowel screening programme was £10 million. 
o In 2007-08 the cost was £27.5 million. 
o In 2008-09 the cost is estimated at £55 million. 
  
 
81 
4.2.4 Comparison of ovarian cancer screening with currently offered cancer-
screening programmes 
It is clear from analysing the three currently offered NHS cancer screening programmes 
that the main aim is to detect disease at an early stage when treatment should be more 
effective.  The UK National Screening Committee (August, 2009) provide criteria for 
appraising the viability, effectiveness and appropriateness of a screening programme 
with key points that must be met as follows: 
 
The Condition 
o The condition should be an important health problem  
o The epidemiology and natural history of the condition, including development 
from latent to declared disease, should be adequately understood and there 
should be a detectable risk factor, disease marker, latent period or early 
symptomatic stage.  
o All the cost-effective primary prevention interventions should have been 
implemented as far as practicable.  
The Test 
o There should be a simple, safe, precise and validated screening test.  
o The test should be acceptable to the population.  
o There should be an agreed policy on the further diagnostic investigation of 
individuals with a positive test result and on the choices available to those 
individuals.  
The Treatment 
o There should be an effective treatment or intervention for patients identified 
through early detection, with evidence of early treatment leading to better 
outcomes than late treatment.  
  
 
82 
The Screening Programme 
o There should be evidence that the complete screening programme (test, 
diagnostic procedures, treatment/ intervention) is clinically, socially and 
ethically acceptable to health professionals and the public.  
o The benefit from the screening programme should outweigh the physical and 
psychological harm (caused by the test, diagnostic procedures and treatment).  
o The opportunity cost of the screening programme (including testing, diagnosis 
and treatment, administration, training and quality assurance) should be 
economically balanced in relation to expenditure on medical care as a whole (ie. 
value for money).  
o Adequate staffing and facilities for testing, diagnosis, treatment and programme 
management should be available prior to the commencement of the 
screening programme. 
 
Each screening programme currently offered has specific age criteria for inclusion and 
screening intervals justified by clinical evidence and preliminary work prior to 
introduction into the NHS screening setting.  In particular, prior to the bowel screening 
programme being introduced a large pilot study was performed to determine the 
feasibility of introducing a national screening programme for colorectal cancer based on 
faecal occult blood testing into the NHS.  The current (2009) policy position of the UK 
National Screening Committee is that “ovarian cancer screening should not be offered 
except in the context of the Medical Research Council randomised control trial”(UK 
National Screening Committee, 2009). This policy was reviewed in July 2006 and will 
be reviewed again in 2009/10. The Medical Research Council (MRC) has funded a 
randomised control trial of ovarian cancer screening, UK Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS) that is due to report in 2010/11. 200,000 
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postmenopausal women have been recruited and randomised to screening involving 
ultrasound and CA125 analysis or randomised to a control group as part of this research.  
 
The same researchers based at University College, London have introduced the United 
Kingdom Familial Ovarian Cancer Screening Study (UKFOCSS). The UKFOCSS is 
investigating whether ovarian screening is beneficial for those women who are at an 
increased risk of developing ovarian cancer.  Researchers are aiming to detect ovarian 
cancer at an early stage when treatment has a higher success rate and prove whether 
screening is effective at detecting cancer and actually save lives (Jacobs, 2009).  The 
UKFOCSS aims to recruit 5000 women, 35 yrs or above with an increased risk of 
developing ovarian cancer due to family history of cancer or are a breast cancer gene 
carrier.  As found from the literature review performed, several studies used this 
approach to screening, however, many others screened only postmenopausal women 
and others pre and postmenopausal women without increased risk of developing ovarian 
cancer. It is therefore, difficult to establish what approach is more „beneficial‟ in 
screening for ovarian cancer as the studies analysed vary in their screening techniques 
and inclusion criteria.  
 
The findings from both the UKCTOCS and UKFOCSS will be vital in determining the 
cost implications of screening to the NHS, what anxieties and fears are associated with 
screening and complications that might arise through screening. This information will 
be used by the UK National Screening Committee to make an informed decision about 
the introduction of an NHS based national screening programme for ovarian cancer. 
 
  
 
84 
4.3 NHS Screening Programme for Ovarian Cancer  
Should the findings from both the UKCTOCS and UKFOCSS provide clinical evidence 
and benefit that ovarian cancer screening is feasible and should be offered in the NHS 
setting, extensive cost analysis will need to be performed and decisions made into which 
screening strategy should be implemented and why.   
4.3.1 Inclusion Criteria 
Through the literature review performed and experience in UK National Screening 
studies, it is clear that two main screening populations and inclusion criteria exist. 
Firstly, screening postmenopausal women aged 50 – 74 years of age as used in 
UKCTOCS (Menon et al., 2005).  Secondly, focusing on those women determined to be 
at high risk of developing ovarian cancer due to family history or a genetic 
predisposition aged 35 years and above, as used in UKFOCSS (Jacobs, 2009). 
However, again through evidence from the literature review and performing 
retrospective studies at Milton Keynes Hospital, a third option may also exist based on 
this researcher‟s opinion.  
 
There is a clear benefit in screening premenopausal women as Tailor et al (2003) 
detected the majority of cancers in this age group and through the retrospective study of 
ovarian cancer cases diagnosed at Milton Keynes Hospital, 17 of the 75 cases were 
found in premenopausal women.  Around 20% of all ovarian cancer cases in the UK are 
found in women below 50yrs of age and therefore, offering screening to all 
premenopausal women would not be justified. Premenopausal women are at lower risk 
of developing ovarian cancer due to age and known to have benign gynaecological 
conditions that increase the number of false positive screening rates using CA125 and 
ultrasound (Jacobs, 2009).  Identifying those women at risk of developing ovarian 
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cancer due to family history of the disease or a genetic predisposition, including 
premenopausal women, as used in UKFOCSS, is also proposed in scenario three.  The 
most successful screening study of the 17 analysed in the literature review was by 
Menon et al (2002) that involved postmenopausal women undergoing a transvaginal 
ultrasound using complex morphological ultrasound criteria following a raised CA125 
result. The highest PPV of all studies analysed was achieved at 37.2% with a sensitivity 
of 100% and specificity of 97%.  It is therefore proposed in the third scenario, that pre 
and postmenopausal women at high risk of developing ovarian cancer and all 
postmenopausal women with a raised CA125 result are offered screening. This 
approach was not found in any of the studies included in the literature review and would 
provide screening to both those at risk of developing ovarian cancer due to age and due 
to a family history or genetic predisposition. 
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4.3.2 Scenario One 
UKCTOCS focused on postmenopausal women from the general population aged 50 to 
74 years of age with 202,638 participants recruited over three years. 13 NHS Hospitals 
in different regions of the UK were involved in the study, meaning an average annual 
recruitment of 5,196 participants per Hospital involved in UKCTOCS.   
 
4.3.3 Scenario Two 
UKFOCSS focuses on women aged 35 years and older determined to be at high risk of 
developing ovarian cancer due to family history of the disease or a genetic 
predisposition. Currently 4550 participants have been recruited into 36 NHS Hospitals 
in different regions of the UK, meaning an average annual recruitment of 63 
participants per Hospital involved in UKFOCSS.  
4.3.4 Scenario Three 
The inclusion criteria used in scenario three will include those women in UKFOCSS 
and postmenopausal women with a raised CA125 result.  Based on Menon et al (2000) 
22,000 women volunteered for screening with 714 (3.25%) found to have an elevated 
CA125 result. Therefore, screening scenario three would expect 63 participants through 
the UKFOCSS inclusion and 3.25% of the 5,196 recruited through UKCTOCS, 
meaning an average annual recruitment of 232 participants per NHS Hospital involved 
in scenario three.  Figure 4.2 provides an overview of the screening population in 
Scenario Three and a breakdown of expected participants recruited based on experience 
in the UKFOCSS at Milton Keynes Hospital and literature reviewed. 
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Figure 4.2 Screening Population in Scenario 3 
 
 
Figure 4.2 provides a flow diagram of scenario three from initial recruitment and initial 
ultrasound and CA125 analysis. The numerical data is based on the UKCTOCS and 
UKFOCSS data with approximately 232 participants expected per NHS hospital 
involved in this suggested screening population and protocol.  If numerical data found 
in the Milton Keynes Hospital audit (Chapter 3) was used to interrogate this scenario, it 
would mean due to the majority of patients diagnosed with ovarian cancer being 
postmenopausal (77%) and as the majority of cases regardless of menopausal status had 
a raised CA125 (92%) the postmenopausal population should have a high sensitivity of 
screen detected disease. As previously mentioned, false positive screening rates are 
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higher in premenopausal women due to a host of benign gynaecological conditions 
(Jacobs, 2009) however, 17 of the 75 cases in the Milton Keynes Hospital Audit were in 
this population with five cases found to have a family history of breast or ovarian 
cancer. Therefore, scenario three provides a means of screening those premenopausal 
women at risk of developing familial ovarian cancer as screening all premenopausal 
women would not be feasible or ethically justified.  
 
4.3.5 Screening Method 
Studies analysed in the literature review varied from those using ultrasound alone for 
screening and others that incorporated biomarker analysis with ultrasound examination.  
Ultrasound examination particularly through the use of transvaginal scanning provides a 
diagnostic, non-ionising, sensitive method of imaging the ovaries and therefore, an ideal 
screening tool. Ultrasound was found to be of particular diagnostic benefit when 
incorporated with a complex ultrasound morphological criteria as used by Menon et al 
(2000), achieving the highest PPV of all studies in the literature review (an example of 
one used in UKFOCSS can be found in Appendix G).  The benefit of incorporating 
biomarker analysis into screening for ovarian cancer was clearly found by Buys et al 
(2005) with a positive predictive value of 1% with ultrasound alone, 3.7% with CA125 
alone and a combined positive predictive value of 23.5%.  The limitations of CA125 are 
acknowledged and have previously been explained however, at present no other 
clinically proven biomarker in the NHS setting for ovarian cancer detection is available. 
 
The surveillance of women offered screening was also found to vary in the studies 
analysed with some reviewing women annually and others screening three to four times 
per year.  Stirling et al (2005) concluded that annual surveillance with ultrasound and 
CA125 is ineffective in detecting tumours at a sufficiently early stage to influence 
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prognosis with three cancers (two FIGO Stage III and one FIGO Stage IV) not being 
detected by screening and presenting in the interim screening period. The retrospective 
study performed at Milton Keynes Hospital also highlights how unsuitable annual 
screening for ovarian cancer is, with case 29 diagnosed with FIGO Stage III disease on 
surgical laparoscopy and a normal CT examination reported just four months prior. 
Therefore, should NHS based ovarian cancer screening be introduced it is clear that due 
to the often aggressive nature of ovarian cancer more frequent intervals of screening 
will be required during a period of 12 months.  
 
The inclusion criteria and screening methods decided upon for NHS implementation 
will have a direct impact in the cost implications for screening. UKFOCSS aims to 
screen participants every 3 months with CA125 and perform annual ultrasound 
examinations, as used in scenario three, based on evidence that annual screening with 
current tests may not provide adequate sensitivity for early stage disease or impact on 
mortality rates (Jacobs, 2009). 
 
4.3.6 Quality Control of a Screening Programme 
Should the UK National Screening Committee decide to implement ovarian cancer 
screening this researcher feels similar steps to the UK Fetal Anomaly Screening 
Programme (FASP) could be used.  The FASP aims to set standards and oversee the 
implementation of a good quality screening programme for all women in England. 
Guidance and standards that must be met are provided with recently employed regional 
screening leads to visit hospitals involved in the screening programme to offer advice 
and assistance at a local level. This approach has already been proven to be effective 
and provide continual guidance and support for those Hospital Trusts offering 
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screening.  The screening method for ovarian cancer regardless of screening population 
decided upon by the National Screening Committee will involve ultrasound examination 
and therefore, Sonographers involved in this screening may require a certain level of 
gynaecological experience and reporting criteria to adhere to. This researcher feels that 
given the nature of ultrasound examinations, double checking of images would not be 
feasible or diagnostically beneficial in every participant however, advice from a senior 
colleague or referring gynaecologist could be sought in difficult or uncertain cases and 
would aid in the learning process of staff involved in a screening programme.  
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4.4 Proposed Cost Analysis for NHS Implementation of Screening 
 
In order to provide a cost analysis of the three screening options, the annual finance 
required will be estimated based on the expected number of participants recruited and 
costs associated with diagnosis, surgical intervention and consultant referral for consent 
and clinical management. It is expected that should NHS based ovarian cancer 
screening be offered, extra facilities may be required on Hospital sites, additional 
equipment such as ultrasound machines and costs associated with recruitment of 
participants. However, these requirements would be individual to the needs of each 
NHS trust and its surrounding population and therefore, not within the scope of this 
study to estimate. Therefore, cost analysis will focus on direct costs applicable to all 
NHS trusts involved in the screening process alone, based on NHS national 
recommended tariff costs. 
 
The following costs were established through collecting financial data from Milton 
Keynes Hospital NHS Foundation Trust Finance Department based on national 
recommended tariff costs: 
 Ultrasound - £65 per examination 
 CA125 - £31 per analysis 
 Laparoscopic surgical procedure – £1,256 
 Consultant Gynaecologist referral –  £158 for initial consultation 
                 £76 per follow-up attendance 
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Cost Analysis for Scenario One – Based on UKCTOCS (Menon et al., 2005) 
 
 
Inclusion Criteria 
o Screen women aged 50 – 74 years of age. 
o Postmenopausal: 
o 12 months amenorrhoea following natural menopause or hysterectomy 
o 12 months of hormone replacement therapy commenced for menopausal symptoms 
Exclusion Criteria 
o Bilateral oophorectomy  
o Currently active non-ovarian malignancy (excluding skin cancer) 
o Women who have had an ovarian malignancy in the past 
o Women at high risk of ovarian cancer due to a familial predisposition 
o Woman participating in other ovarian cancer screening trials 
 
 Ultrasound 
Examination 
CA125  
 
Laparoscopic surgery Gynaecological 
Consultation 
Estimated Total 
Costs per regional 
centre 
Annual Cost per participant £65 £31 £1,256 per laparoscopy 
required 
£158 £257 
Annual Cost for 5,196 
participants 
(expected number of 
participants based on 
UKCTOCS experience) 
£337,740 £161,076 £15,663 
(*0.24% of 5,196 participants) 
£820,968 £1,335,447 
*Based on research by Menon et al (2005) using the UKCTOCS strategy of the 6,532 women who underwent screening, 144 women with an elevated risk 
from CA125 had a transvaginal ultrasound resulting in 16 women undergoing surgery (0.24% of total number screened). 
 
Table 4.2 Cost Analysis for Scenario One – Based on UKCTOCS 
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Cost Analysis for Scenario Two – Based on UKFOCSS (Jacobs, 2009) 
 
 
Inclusion Criteria 
o Women aged 35 years and over. 
o Inclusion in the study will be on the basis of a family history of cancer confirmed by histopathology report or death certification or a 
documented mutation of an ovarian cancer causing gene.  
Exclusion Criteria 
o Bilateral oophorectomy  
o Women less than 35 years of age 
o Woman participating in other ovarian cancer screening trials 
 
 
Table 4.3 Cost analysis for Scenario Two – Based on UKFOCSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Ultrasound 
Examination 
CA125 
3 per annum 
Laparoscopic surgery Gynaecological 
Consultation 
Estimated Total 
Costs per regional 
centre 
Annual Cost per 
participant 
£65 £31 x 3 £1,256 per laparoscopy 
required 
£158 £348 
Annual Cost for 63 
participants  
(expected number of 
participants based on 
UKFOCSS experience) 
£4095 £5859 £2057 
(*2.6% of the 63 participants) 
£9954 £21,965 
*Based on research by Stirling et al (2005) using UKFOCSS strategy of the 1,110 women who underwent screening, 29 women required surgery 
(2.6% of the total number screened). 
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Cost Analysis for Scenario Three – Based on Literature Review and Retrospective Study 
 
Inclusion Criteria 
o Women aged 35 years and over at increased risk of developing ovarian cancer due to family history or a genetic predisposition 
(UKFOCSS). 
o Postmenopausal women with a raised CA125 result (>30U/ml). 
o 12 months amenorrhoea following natural menopause or hysterectomy 
o 12 months of hormone replacement therapy commenced for menopausal symptoms 
 
Exclusion Criteria 
o Bilateral oophorectomy 
o Woman participating in other ovarian cancer screening trials 
 
 
 
Table 4.4 Cost Analysis for Scenario Three 
 Ultrasound Examination CA125 
3 per annum 
Laparoscopic surgery Gynaecological 
Consultation 
Estimated Total 
Costs per regional 
centre 
Annual Cost per 
participant 
£65 £31 x 3 £1,256 per laparoscopy 
required 
£158 £348 
Annual Cost for expected 
232 participants  
 
£15,080 £21,576 £7,576 
(*2.6% of the 232 
participants) 
£36,656 £80,888 
*Based on research by Stirling et al (2005) using UKFOCSS strategy of the 1,110 women who underwent screening, 29 women required surgery (2.6% of 
the total number screened). 
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4.5 The Impact on Milton Keynes Hospital in offering an ovarian 
cancer-screening programme 
 
Milton Keynes Hospital NHS Foundation Trust has been involved in the UKFOCSS for 
over three years and has recruited in that time 30 eligible participants.  Participation in 
this study currently requires the following: 
o A named consultant gynaecological surgeon to be aware of the study design, 
consent eligible participants and receive referrals if suspicion of cancer exists or 
medical advice is required. 
o A research nurse to co-ordinate the participants and liaise with the main research 
centre when ultrasound examinations and blood tests are required. 
o A reporting sonographer with gynaecology experience to perform annual 
ultrasound examinations on participants and more frequent examinations or 
follow-up scans as required. 
 
The main research centre based at the University College, London (UCL) co-ordinates 
the participant‟s management from the blood analysis and ultrasound reports. The 
research nurse is then informed should a participant need a referral to the named 
gynaecologist or follow-up ultrasound examinations. Therefore, the involvement of 
Milton Keynes Hospital in this study is relatively small as the main workload is 
managed by the main research centre.  Should the UK National Screening Committee 
decide that ovarian cancer screening should be offered by a hospital such as Milton 
Keynes NHS Foundation Trust, the impact would depend on which scenario to 
implement. However, as the implementation would be a screening programme, rather 
than research based studies, Milton Keynes Hospital would have a dramatically 
increased involvement. 
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4.5.1 Impact of Scenario One 
The impact of scenario one (based on UKCTOCS) would be substantial to Milton 
Keynes Hospital as approximately 5,196 participants would require screening. This 
scenario would not only cost in the region of £1,335,447 as explained in Table 4.2, but 
also require additional facilities and staffing associated with a screening programme of 
this size. This scenario would require several full-time members of staff to be involved 
in the screening programme including: 
 Gynaecological surgeon(s) to refer patients with abnormal screening tests, 
perform surgical interventions and manage treatment options if malignant 
disease is diagnosed. 
 Several reporting sonographers would be required to perform ultrasound 
examinations on such a large number of anticipated women recruited with new 
equipment purchased for the screening. A number of additional ultrasound 
examinations would also be required in the interim periods due to abnormal 
CA125 levels. 
 Several staff familiar with screening would be needed to co-ordinate consent and 
eligibility checks on recruited women, manage blood tests and ultrasound 
examination results. 
 
A separate screening unit on site would be required at Milton Keynes Hospital as 
current facilities could not manage the number of women offered screening.  It is 
expected that many cases would require discussion in multi-disciplinary team meetings 
when monitoring of ovarian cysts and CA125 levels are equivocal. Therefore, a large 
amount of time would be needed to decide on patient management. The costs of 
scenario one are therefore, high and in excess of those predicted in Table 4.2, as new 
premises would be required, multiple members of staff involved and ultrasound 
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equipment purchased. Recruitment of possible eligible women for screening would be 
substantial as CA125 levels would be required from the outset.    
 
The main benefit of scenario one would be through offering screening to those women 
at risk of developing ovarian cancer due to age as over 80% of cases are diagnosed in 
women over 50yrs of age, with a steep increase in incidence in postmenopausal women 
(aged 55yrs and over), as seen in Figure 1.3 (Cancer Research UK, 2009).  No screening 
would be offered to those women at risk of developing ovarian cancer due to family 
history of the disease, a genetic predisposition of the disease or premenopausal women.  
Scenario one uses a biomarker that has been proven to be limited in its sensitivity of 
detecting ovarian cancer with elevated levels found in 29-75% of cancers diagnosed at 
the earliest stage (Menon & Jacobs, 2002). Therefore, scenario one differs from several 
other screening studies reviewed as ultrasound was often used alongside CA125 
analysis, however, in scenario one only those women with elevated CA125 levels 
undergo an ultrasound examination.  The only positive aspect of using CA125 in this 
screening population is the specificity of CA125 is expected to improve as 
premenopausal women are not included and are known to have elevated CA125 levels 
due to benign ovarian disease, fibroids, endometriosis and pelvic inflammatory disease, 
summarised in Table 1.6 (Menon & Jacobs, 2002). 
 
4.5.2 Impact of Scenario Two 
The impact of scenario two on Milton Keynes Hospital (based on UKFOCSS) would be 
far less as approximately 63 (expected number based on UKFOCSS national 
experience) participants would require screening. Scenario two is expected to cost in the 
region of £21,965 (Table 4.3) in direct screening costs for this number of participants. 
This cost and workload would therefore, be manageable in the same or similar manner 
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at present with patients co-ordinated by a nurse with screening experience who co-
ordinates eligibility checks, consent and the screening results, with ultrasound 
examinations performed in the imaging department.  The costs of scenario two would 
therefore, be significantly less in comparison with scenario one, as fewer staff would be 
required, no new premises or at the present time, ultrasound equipment required.  
 
Scenario two focuses on familial ovarian cancer and therefore, does not offer screening 
to those at risk of developing the disease due to age. As scenario two incorporates 
premenopausal women it is expected that additional ultrasound examinations and 
gynaecological reviews would be required due to the known elevated CA125 levels 
associated with benign gynaecological conditions in this screening population. 
Therefore, costs associated with additional ultrasound examinations and gynaecological 
referrals must be considered as clinical management of not only CA125 levels will be 
required but also incidental findings of benign gynaecological disease (Menon et al, 
2000).  A higher proportion of surgical interventions due to benign gynaecological 
pathology associated with premenopausal women is expected (Stirling et al, 2005) and 
as shown in the second retrospective study performed at Milton Keynes Hospital, the 
majority of false positive imaging cases were in premenopausal women.  Therefore, a 
named gynaecologist that can be referred to directly would be frequently required to 
coordinate additional ultrasound examinations or further diagnostic imaging to decide 
when surgical intervention is necessary. 
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4.5.3 Impact of Scenario Three 
The impact of scenario three lies somewhere between scenarios one and two with 
approximately 232 participants expected to be recruited.  This researcher‟s opinion for 
screening was based on the literature review performed and retrospective studies at 
Milton Keynes Hospital. Scenario three would involve both a financial cost in the 
region of £80,888 (Table 4.4), with several members of staff required and space for 
clinics to be held for confirmation of eligibility, consent and imaging.  It is expected 
that additional staff dedicated to the screening programme would be required to take 
blood for initial CA125 screening and eligibility checks, but also to manage CA125 
analysis every three - four months and coordinate ultrasound examinations as required.   
 
The main benefit of scenario three is that screening is offered to those women at 
increased risk of developing ovarian cancer due to age and familial or genetic 
predisposition and therefore, focusing on women at increased risk of the disease 
regardless of menopausal status.  As annual screening was found to be ineffective in 
detecting tumours at a sufficiently early stage to influence prognosis (Stirling et al, 
2005, Gaarenstroom et al, 2006 and Fishman et al, 2005), monitoring of CA125 levels 
is proposed every three - four months with ultrasound examination performed annually 
or when required based on CA125. A single reporting sonographer could perform 
ultrasound examinations as required on those women recruited with the named 
gynaecological surgeon receiving referrals for clinical management. Additional 
facilities would be required for this scenario at Milton Keynes Hospital and the costs of 
this scenario would be higher than in scenario two, however, more women at risk of 
developing ovarian cancer would be offered screening. 
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4.6 Conclusion of Cost Analysis 
 
It is clear from the cost analysis of the three scenarios that due to the different inclusion 
criteria used there is a large difference in the expected number of participants with 
UKCTOCS expected to recruit 5,196, UKFOCSS expected to recruit 63 and scenario 
three expected to recruit 232.  This difference obviously has a significant impact on the 
costs associated with the screening proposed with UKCTOCS costing £1,335,447, 
UKFOCSS costing £21,965 and scenario three costing £80,888 per annum.  The cost 
analysis performed has provided an overview of direct costs applicable to all NHS trusts 
involved in the screening process alone, based on NHS national recommended tariff 
costs.  Each NHS trust involved in a screening programme will have individual needs 
for facilities, staffing and equipment. There will also be significant costs associated with 
the recruitment of participants, eligibility checks and additional ultrasound 
examinations / CA125 analysis for surveillance. 
 
The UK National Screening Committee will therefore, have to decide once the findings 
of UKCTOCS are published in 2010/11 as to the cost benefit of offering ovarian cancer 
screening in the NHS setting. An annual cost of at least £1,335,447 (if based on 
UKCTOCS) should be expected per NHS Trust involved, based on this basic cost 
analysis, in addition to individual NHS trusts needs to offer such screening. The results 
of UKFOCSS will not be known for some time as the study is still ongoing at the time 
of this research. Scenario three based on this researcher‟s opinion offers a novel 
screening protocol from those analysed in the literature review and a means for those 
women at risk of developing ovarian cancer due to age or by having familial / genetic 
predisposition ovarian cancer screening. 
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5 DISCUSSION 
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5.1 Ovarian Cancer Screening 
 
The aim of this project was to investigate the feasibility of an NHS based ovarian cancer 
screening programme with regard to current clinical evidence, resources required, costs 
involved and implications for a local NHS Foundation Trust.  In order to achieve this 
aim several research methods have been used to provide evidence based conclusions 
and justified recommendations. As NHS based ovarian cancer screening is not currently 
recommended by the UK National Screening Committee a research project of this 
nature is of relevance both at a local level in investigating the requirements of a 
screening service and at a national level in key points found from the systematic 
literature review and retrospective studies. 
 
5.1.1 Why offer ovarian cancer screening? 
Ovarian cancer accounts for more deaths than all the other gynaecological cancers 
combined. In 2007, the most recently available statistics, 4,317 UK women died from 
ovarian cancer, accounting for around 6% of all female deaths from cancer (Cancer 
Research UK, 2009).  The majority of women who develop ovarian cancer have few 
symptoms until the cancer has spread, by then treatment is more difficult.  Symptoms 
experienced are vague and difficult to recognise particularly in the early stages of the 
disease (Rufford et al., 2007).  Through the retrospective study performed the largest 
group of cases at Milton Keynes Hospital were diagnosed with advanced FIGO Stage 
IV disease (31%) meaning distant metastasis and a five-year survival rate of 15%, in 
comparison to over 85% if diagnosed at Stage I (Menon and Jacobs, 2002).   Cases 17, 
39, 42 and 49 highlight the problems of vague symptoms as due to changes in bowel 
habit with weight loss, bowel pathology was suspected by referring general practitioners 
rather than ovarian disease. Therefore, symptoms cannot be used to screen for this 
disease.  The majority of patients (93%) diagnosed with ovarian cancer in Milton 
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Keynes Hospital were due to sporadic disease rather than familial and therefore, patients 
were not known to be at risk of developing ovarian cancer due to a familial or genetic 
predisposition. All cases in the retrospective study with confirmed ovarian cancer had 
features of malignancy on imaging prior surgical intervention. Through the second 
retrospective study 35 cases over an 18 month period highlight the limitations of 
imaging, as ovarian pathology was suggested of unknown nature. Many of these cases 
simply required follow-up with ultrasound or MRI/CT, resulting in 40% still requiring 
surgical intervention to reach a final diagnosis of non-malignancy.   
 
5.1.2 Who should be offered screening? 
A systematic literature review was used to provide an insight into recent published 
studies investigating ovarian cancer screening and each study analysed for inclusion 
criteria and methods adopted.  This review highlighted the range of screening methods 
used with six different inclusion criteria (Figure 2.3) in the 17 studies analysed with 
variations found in age, menopausal status and associated risk of developing ovarian 
cancer due to family history of the disease as follows: 
1. Peri and postmenopausal women. 
2. Postmenopausal women. 
3. Postmenopausal women with raised CA125. 
4. Premenopausal and postmenopausal women. 
5. Premenopausal and postmenopausal women at high risk of developing ovarian 
cancer. 
6. Women >50yrs of age and women >25 yrs of age at high risk of developing 
ovarian cancer. 
 
Both findings from the first retrospective study and Cancer Research UK (2009) 
indicate that around 80% of women diagnosed with ovarian cancer are above the age of 
50 which equates to 77% of women being postmenopausal. However, 17 women from 
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the 75 diagnosed with cancer at Milton Keynes Hospital were premenopausal with three 
of this group diagnosed with advanced FIGO Stage IV disease. A high incidence of 
premenopausal cancers was also found by Tailor et al (2003) with 15 of the 20 cancers 
detected in this group.  Literature suggests around 5-10% of all cases of ovarian cancer 
are the result of an inherited gene or genes (Sekine, 2001).  Five cases from the 
retrospective study were found to have a documented family history of breast or ovarian 
cancer resulting in a 6.7% incidence of familial ovarian cancer at Milton Keynes 
Hospital. Therefore, this research implies that should ovarian cancer screening be 
offered in the NHS setting both pre and postmenopausal women are at risk of 
developing the disease and whilst some may have a family history or carry a BRCA 
gene mutation, a large proportion of cancers will result from sporadic disease 
particularly in postmenopausal women.  
 
5.1.3 How to screen for ovarian cancer 
Variations in screening tools used were found through the systematic literature review 
with six studies using ultrasound examination alone and 11 studies incorporating the use 
of tumour markers alongside ultrasound.  The studies analysed that incorporated serum 
tumour markers have a large variation in their sensitivity and positive predictive values.  
The benefit of incorporating biomarker analysis into screening for ovarian cancer was 
clearly found by Buys et al (2005) with a positive predictive value of 1% with 
ultrasound alone, 3.7% with CA125 alone and a combined positive predictive value of 
23.5%.  The most successful screening study of the 17 analysed was by Menon et al 
(2000) that involved postmenopausal women undergoing a transvaginal ultrasound 
using complex morphological ultrasound criteria following a raised CA125 result, 
resulting in the highest positive predictive value of all studies analysed at 37.2%.  
Through the retrospective study at Milton Keynes Hospital, 73 of the 75 cases had a 
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pelvic tumour detected through imaging often through the use of ultrasound 
examination with secondary disease, if present, detected in all cases on CT/MRI. The 
limitations of both ultrasound and CA125 are well documented and have already been 
discussed however, as no other clinically proven biomarker other than CA125 is 
presently available and as 92% of patients with ovarian cancer in the retrospective study 
had a raised CA125 level, it is clear both imaging and CA125 analysis are required for 
screening in the NHS setting. Transvaginal ultrasound has been recognised for several 
years as the „gold standard‟ of ultrasound clinical practice, offering improved image 
resolution and visualisation of the female pelvis. However, it is important to address the 
efficacy of performing invasive examinations on screening patients. Andrykowski et al 
(2007) and Drescher et al (2004) found that compliance of women to a semi-annual 
screening protocol diminished rapidly. In comparison Pavlik et al (2000) found high 
levels of continuation through annual ultrasound screening with 96% of women 
returning for visits within two years, indicating that women take ovarian cancer disease 
seriously and it is of consequence to them through continuing with screening. 
 
5.1.4 How often to screen for ovarian cancer 
How often to perform ovarian cancer screening is of great importance when 
investigating the impact to an NHS hospital both in clinical diagnosis and cost 
implications with variations found as shown in Tables 4.2, 4.3 and 4.4. Stirling et al 
(2005) found ultrasound and CA125 when performed annually ineffective in detecting 
tumours at a sufficiently early stage to influence prognosis with three cancers presenting 
within the 12 month screening period.  Similar findings were observed by Gaarenstroom 
et al (2006) and Fishman et al (2005) with advanced cancers being detected at screening 
or presenting in the interim screening period with symptoms. Case 29 in the 
retrospective study also highlights how unsuitable annual screening for ovarian cancer 
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is and how quickly it can develop and spread. This case had FIGO Stage III disease 
detected on surgical laparoscopy however, a normal CT examination was reported just 
four months prior to diagnosis.  Therefore, both literature and the retrospective study 
suggests that monitoring of ovarian appearance and biomarker analysis is required more 
frequently than every 12 months and as frequent transvaginal scanning may result in 
poor participant compliance, CA125 analysis every three to four months is proposed 
alongside annual transvaginal ultrasound as used in the UKFOCSS. 
 
5.1.5 Impact to a local NHS Trust 
It is clear from the cost analysis in chapter four, that due to the different inclusion 
criteria used there is a large difference in the expected number of participants and 
impact on the costs associated with screening. Scenario three was proposed based on the 
systematic literature review and retrospective studies performed meaning that women at 
risk of developing ovarian cancer due to family history or a genetic predisposition and 
all postmenopausal women with a raised CA125 result are offered screening. This 
approach was not found in any of the studies included in the literature review and 
provides a novel method of offering screening to those at risk of developing the disease. 
It was decided that offering screening to all premenopausal women would not be ethical 
or justified as they are at lower risk of developing ovarian cancer due to age and not 
diagnostically beneficial due to increased false positive screening rates caused by 
benign gynaecological conditions using both ultrasound and CA125 (Jacobs, 2009). 
Therefore, if this screening method is adopted in a local NHS Hospital such as Milton 
Keynes a cost in the region of £80,888 per annum would be expected. It is anticipated 
that these costs would be higher as a number of participants will require more than one 
ultrasound examination per annum and additional CA125 analysis for surveillance.   
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Regardless of the method of screening decided upon for NHS introduction, specialist 
screening staff as currently used in breast and bowel screening at Milton Keynes 
Hospital will be required in order for the screening to be managed appropriately. A wide 
variation in the number of participants is predicted depending on who is offered 
screening by the UK National Screening Committee.  As shown in Figure 4.1, Miller et 
al (2001) provides a breakdown of where costs are associated with screening and also an 
insight into the time implications involved in following up participants and deciding on 
management depending on screening results obtained. 
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5.2 Conclusion 
 
It is apparent from the literature on ovarian cancer screening that internationally 
extensive research is performed however, there is lack of consensus on who to offer 
screening to, and the most efficacious way of offering it. A wide variation of screening 
methods were found all varying in their inclusion criteria and tools for early cancer 
detection with many using ultrasound examination and CA125 analysis for screening. 
The majority of ovarian cancer cases diagnosed at Milton Keynes Hospital over a five 
year period were found to have advanced (FIGO Stage IV) disease at time of diagnosis, 
meaning a five-year survival in the region of 15% (Menon and Jacobs, 2002).  
Statistically significant differences were found in the ages of women diagnosed with 
FIGO classification stages of disease and CA125 levels. A wide age range of women 
were diagnosed with ovarian cancer with varying symptoms experienced and clinical 
presentation. The retrospective studies highlight the limitations of imaging and often 
ultrasound in the characterisation of ovarian lesions.  
 
Key aspects of this research could now be developed further from the retrospective 
studies, ultrasound reporting and national implementation of ovarian cancer screening. 
Further analysis of data collected at Milton Keynes Hospital could compare groups of 
women diagnosed with ovarian cancer to determine if there are any similarities with 
lifestyle or family history of cancer not documented in the medical notes.  The most 
successful screening study found was performed by Menon et al (2000) that 
incorporated using complex ovarian morphology classification achieved a positive 
predictive value of 37.2%. Kurjak et al (2005) also provides a sensitivity of 100% and 
specificity of 99.4% using three-dimensional ultrasound and power Doppler. Therefore, 
as provided in Appendix G, it may be useful to incorporate a complex ovarian 
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morphology classification system into radiological reporting on a routine NHS based 
ultrasound examination and should screening be introduced, it would provide a 
consistent method for all practitioners to adhere to.  Three dimensional ultrasound is not 
currently routinely used in the NHS however, based on results published by Kurjak et al 
(2005) it could provide a means of improving the specificity of lesion characterisation.  
Further work would also be required based on this research into costs involved in an 
ovarian cancer screening programme. It is clear the large variations in expenditure 
based on scenarios discussed in this paper and the NHS alongside NICE would need to 
ensure adequate funding is in place prior to implementation of a new NHS based 
programme. This researcher feels that an ovarian cancer screening programme is only 
feasible with the necessary resources and specialist staff alongside appropriate national 
guidance and support.  The financial impact of such a programme is expected to be 
large however, as shown from the literature review early ovarian disease can be detected 
prior to symptoms developing ie: screen detected, and therefore, should provide more 
effective treatment at an earlier stage. The suggested scenario three that includes both 
premenopausal and postmenopausal women is aimed at detecting ovarian cancer in 
groups at risk of the disease due to family history and age.  This researcher suggests that 
based on literature and the local audit performed, an inclusion criterion such as this is 
vital as although the majority of cases were postmenopausal women, many cases of 
premenopausal women were also found in studies reviewed. Obviously, CA125 is a 
biomarker with known limitations in its sensitivity and specificity however, given that 
the majority (92%) in the local audit performed had a raised level, this screening test is 
required in scenario three until a more diagnostically useful marker is developed.  
 
Investigating how implementation of screening at a national level could be performed, 
should the National Screening Committee decide that screening will be offered in the 
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NHS.  As breast screening is based at a hospital or in a mobile screening unit and 
cervical screening is typically based at a local general practitioner clinic, it would be 
interesting to see whether ovarian cancer screening could be offered by one NHS Trust 
providing screening services for a region or if every Trust would need to offer a 
screening service. It is clear through both the literature reviewed and the retrospective 
studies that annual screening is inadequate for early detection of disease however, 
performing transvaginal scans every three to four months would not be feasible in the 
NHS setting. Research is ongoing into the development of a biomarker that proves more 
sensitive to early disease and specific to ovarian malignancy, as clearly this is urgently 
required in clinical practice (Gogoi et al, 2006).  Knowledge about the characteristics of 
ovarian cancer, stages, grades, histologies, inheritance factors and aetiology is required 
to define criteria for searches of possible useful markers. Should a new more sensitive 
biomarker be found the application and translation from the laboratory to clinical use is 
vital. With the additional requirement that all marker analysis must be undertaken in a 
manner, which is suitable for use within an NHS Hospital where equipment, which is 
able to undertake detailed molecular analyses, may not be available. 
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APPENDIX A  
Studies Included from Cochrane Library Database Search 
Author and Year  
of Publication 
Study Objectives and Study Design SIGN  
Grading 
Key Findings 
Study No° 1 
(Andersen et al., 
2007) 
 
Investigate the effects of participation in an ovarian 
cancer screening programme on worry about cancer risk 
and quality of life. Randomised controlled clinical trial 
with two groups – one group assigned to screening and 
risk counselling and one group randomised to usual care 
alone. 
1+ Ovarian cancer screening does not have significant negative effects on 
participants, at least when they do not receive abnormal results. 
 
For those who receive abnormal results, screening may have long-term 
effects and increase worry about cancer risk. 
Study N° 2 
(Bell et al., 1998) 
Systematic review to provide the NHS Health 
Technology Assessment programme with an overview 
of the results of research evaluating screening for 
ovarian cancer. 
 
 
2++ Wide variations in inclusion criteria and modalities used for screening 
study participants. Uncontrolled screening studies cannot provide reliable 
evidence concerning the effect of ovarian cancer screening on health 
outcomes such as mortality and quality of life. 
Study N° 3 
(Buys et al., 2005) 
Ovarian cancer screening with transvaginal ultrasound 
(TVS) and CA125 evaluated in the Prostate, Lung, 
Colorectal and Ovarian (PLCO) trial.  
1++ Positive predictive value with CA125 was 3.7%, 1.0% for an abnormal 
TVS and 23.5% if both testes were abnormal.  Effect of screening on 
ovarian cancer mortality in the PLCO cohort has yet to be evaluated. 
Screening identified early and late stage neoplasms with relatively low 
predictive value. 
Study N° 4 
(Drescher et al., 
2004) 
Report on rates of compliance with an ovarian cancer 
screening protocol using CA125 and transvaginal 
ultrasound.   
 
292 women at average to intermediate risk for 
developing ovarian cancer were randomly assigned to 
arms of a controlled clinical trial. 
1+ Despite extensive follow-up, compliance of average and intermediate risk 
women to an ovarian cancer screening protocol requiring semi-annual 
screening diminishes rapidly. Semi-annual screening incorporating TVS 
may be too intensive for use in this population. 
Study N° 5 
(Jacobs et al., 1999) 
Pilot randomised control trial to assess multimodal 
screening with sequential CA125 and ultrasound. 
 
Postmenopausal women randomised to a control group 
and screened group. 
1+ A positive predictive value was 20.7%. 
Median survival of women with index cancers in the screened group was 
72.9 months and in the control group was 41.8 months. 
 
Results show a multimodal approach to ovarian cancer screening in a 
randomised trial is feasible and justify a larger randomised trial to see 
whether screening affects mortality. 
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Study N° 6 
(Jeyarajah et al., 
1999) 
 
Randomised control trial to assess correlation between 
CA125 elevation, a past history of cancer and future risk 
of non-gynaecological cancer among asymptomatic 
postmenopausal women. 
22,000 women included in study. 
1+ Asymptomatic postmenopausal women who have elevated CA125 are at 
substantially increased risk of gynaecologic cancer. No increased risk of 
breast carcinoma or other non-gynaecological cancer. Previous history of 
breast carcinoma is associated with CA125 elevation it is not a predictor 
of recurrence. 
Study N° 7 
(Lacey et al., 2006) 
Evaluation of positive predictive values of CA125 or 
transvaginal ultrasound screening for ovarian cancer 
according to family history or breast or ovarian cancer. 
Randomised control trial with 28,460 women receiving 
baseline and annual CA125 and transvaginal ultrasound 
examinations. Women classified as average, moderate 
and high risk based on family history or due to a 
personal history of breast cancer. 
1+ Probabilities of abnormal annual CA125 and transvaginal ultrasound 
screens were similar across groups. 
 
Ovarian cancer was more likely to be diagnosed after an abnormal 
screening result among women at higher family history-based risk than 
among women at lower risk. 
Study N° 8 
(Lafata et al., 2004) 
Evaluation of medical and non-medical costs associated 
with false-positive prostate, lung, colorectal and ovarian 
cancer screens. 1,087 trial participants were identified 
enrolled in a large managed care organisation. Medical 
care use and costs were compiled from automated 
resources and trial data.   
2 43% of the study sample incurred at least one false-positive cancer screen 
with the majority (83%) receiving follow-up care. 
 
Significantly higher medical care expenditures in the year following 
screening were found among those with false-positive screen. The 
adjusted mean difference was $1,024 for women and $1,171 for men.  
Study N° 9 
(Menon et al., 
2005) 
 
 
To evaluate prevalence screening in the first prospective 
trial of a new ovarian cancer screening strategy (risk of 
ovarian cancer (ROC) algorithm) on the basis of age and 
CA125 profile. 
 
Postmenopausal women randomly assigned to a control 
group and screened group. Those with elevated values 
underwent transvaginal ultrasound and those with 
persistently equivocal ultrasound were referred to a 
gynaecologist. 
1++ 13,282 were recruited. 6,682 were randomly assigned to screening. 16 
women underwent surgery – 11 had benign pathology, one woman had 
ovarian recurrence of breast cancer, one woman had borderline and three 
women had primary invasive epithelial ovarian cancer. Specificity and 
positive predictive value for primary invasive epithelial ovarian cancer 
were 99.8% and 19% respectively.  
 
An ovarian cancer screening strategy using the ROC algorithm is feasible 
and can achieve high specificity and positive predictive values in 
postmenopausal women. 
Study N° 10 
(Rufford et al., 
2007) 
 
Randomised control trial to determine the feasibility of 
screening for ovarian cancer using symptoms as 
selection criteria. 390 General Practitioner surgeries 
were included with rapid access to ultrasound and 
CA125 for women suffering from symptoms that may be 
caused by ovarian cancer. 
1+ 23 women had abnormal findings on ultrasound. 20 managed 
conservatively and 3 surgically.  No ovarian cancer cases were detected in 
this pilot study, possibly due to the size of the cohort. 
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APPENDIX B 
Studies Included from SCOPUS Database Search 
Author and Year  
of Publication 
Study Objectives and Study Design SIGN  
Grading 
Key Findings 
Study N° 1 
(Andersen et al., 
2002) 
Reports of perceived risk of ovarian cancer, worry, and 
screening use in a large sample of women. Well 
designed cohort study. 3257 women participated by 
completing a survey on ovarian cancer risk. 
2++ Family history did predict perceived risk, difficulties due to worry and use 
of ovarian cancer screening. Most women over-estimated their risk of 
developing ovarian cancer. 
 
Some average-risk women get screening although it is not recommended 
outside of randomised control trials and a significant percentage of women 
at high risk fail to get recommended screening. 
Study N° 2 
(Andrykowski et 
al., 2007) 
Identification of clinical, demographic, dispositional and 
attitudinal variables associated with return for routine, 
annual TVS screening for ovarian cancer. Well-designed 
cohort study. 
 
585 asymptomatic, average to high risk women 
participating in a university-based ovarian cancer-
screening programme. 
2++ Despite recommendations to return in 12 months for screening, over 25% 
of the sample did not return for repeat TVS screening within 24 months of 
their baseline TVS. Possessing more than 12 years of education was 
associated with a greater likelihood of returning for screening.  
 
Assuming the effectiveness of cancer screening is predicted on timely 
repeat screening, the results in this study are worrisome and suggest the 
need to develop effective means of increasing the proportion of women 
returning for repeat screening. 
Study N° 3 
(Bosse et al., 2006) 
Evaluation of the accuracy of TVS in combination with 
CA125 to detect ovarian cancer in women at hereditary 
risk for ovarian cancer. A prospective cohort study of 
676 women including 85 BRCA mutation carriers. 
 
Surgical intervention was performed if TVS revealed a 
suspicious cyst or elevated CA125 levels. 
 
2++ 10 women underwent histological verification that revealed one serious 
cystadenocarcinoma stage 1c. No interval ovarian cancer occurred. 
Specificity of surgical intervention reached 98.7% and a positive 
predictive value of 10%. The low positive predictive value is due to the 
unexpectedly low incidence of ovarian cancer. 
 
Large scale investigations are needed to further evaluate accuracy and 
effectiveness of ovarian cancer screening for women at high risk. 
Study N° 4 
(Crayford et al., 
2000) 
Whether some benign ovarian cysts can develop into 
cancerous cysts is not known. Cohort follow-up of 5479 
asymptomatic women participating in ultrasound based 
screening was assessed to determine whether the 
removal of persistent ovarian cysts from these women 
was associated with a reduction in the number of deaths 
from ovarian cancer. 
2++ Removal of persistent ovarian cysts was not associated with a decrease in 
the proportion of expected deaths from ovarian cancer. 
 
For population-based screening of healthy women without a family 
history of ovarian cancer, a screening test is required that is specific and 
sensitive to early malignant disease. 
  
 
122 
Study N° 5 
(DePriest and 
DeSimone, 2003) 
 
Study reports on two cohort ultrasound based screening 
studies using simplistic abnormality criteria. Kentucky 
trial screened 14,469 women. Hirosaki trial screened 
51,550 women. 
2++ 180 women underwent surgery in the Kentucky trial with 17 ovarian 
cancers detected, 11 of which were invasive epithelial lesions. 344 women 
underwent surgery in the Hirosaki trial with 22 ovarian cancers detected. 
Both studies showed the low positive predictive value of ultrasound 
screening.   
Study N° 6 
(Fishman et al., 
2005) 
 
Investigation into the usefulness of ultrasound in the 
detection of early-stage epithelial ovarian cancer in 
asymptomatic high-risk women who participated in the 
National Ovarian Cancer Early Detection Programme. 
Cohort study of 4526 women – both pre and 
postmenopausal. 
 
2++ A total of 98 women with persistent adnexal masses were identified, with 
49 invasive surgical procedures performed diagnosing 37 benign tumours 
and 12 gynaecologic malignancies. Two women had stage 3 ovarian 
cancer. All cancers were detected in asymptomatic women who had 
normal ultrasound and physical examinations 12 and 6 months before the 
cancer diagnosis.  
Study demonstrated the limited value of diagnostic ultrasound 
examination as an independent modality for the detection of early stage 
epithelial ovarian cancer. 
Study N° 7 
(Gaarenstroom et 
al., 2006) 
Cohort screening study of 269 women at high risk of 
hereditary ovarian cancer is reported in this paper. 
Screening was performed using TVS and CA125 testing. 
113 of the 269 women had a breast cancer gene (BRCA) 
mutation.  127 of the 269 women underwent a salpingo-
oophorectomy. 
2++ In eight women having both elevated CA125 levels and abnormal 
ultrasound findings a malignancy was found- one borderline, one stage 1a, 
one stage IIIb and one stage IIIc were detected at first screening visit. One 
stage IIIb and one stage IIIc were detected at the second screening visit 
after 12 months. Two stage IIIc and one stage IV were detected 8 and 10 
months after the first screening visit. Conclude that the efficacy of 
screening women at high risk of ovarian cancer seems poor because the 
majority of cancers were detected at an advanced stage. 
Study N° 8 
(Goff et al., 2007) 
Case control study of 149 women with ovarian cancer, 
including 255 women who were in a screening 
programme and 233 women who were referred to pelvic 
ultrasound. Symptom types, frequency, severity and 
duration were compared between cases and controls. 
 
2+ Symptoms that were associated significantly with ovarian cancer were 
pelvic/abdominal pain, urinary urgency/frequency, increased abdominal 
size, difficultly eating/feeling full when they were present for <1yr and 
occurred >12 days per month. Symptoms in conjunction with their 
frequency and duration were useful in identifying women with ovarian 
cancer. 
Study N° 9 
(Hensley et al., 
2003) 
Recommendations for women at high risk of ovarian 
cancer include prophylactic salpingo-oophorectomy 
(PSO) or screening with ultrasound and CA125. The 
best strategy for improving survival and maintaining 
quality of life is not known.  
 
High-risk women >30yrs enrolling in a screening study 
completed quality of life perception measurement. 
2++ Premenopausal women perceive their ovarian cancer risk to be higher, 
report greater ovarian cancer risk-related anxiety and are more likely to 
have false-positive screening results than postmenopausal women.  Few 
high-risk women elect PSO in the short term. Knowledge of the frequency 
of false-positive screening results and psychosocial outcomes is important 
for high-risk women choosing strategies for managing ovarian cancer risk. 
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Study N° 10 
(Kurjak et al., 
2005) 
Cohort study to determine whether introducing three-
dimensional (3D) ultrasonography with power Doppler 
as a primary screening test for ovarian cancer improves 
the accuracy of ovarian cancer screening. 
 
Cohort study of 3,201 peri and postmenopausal 
asymptomatic women aged >50yrs. 
2++ 25 patients (0.8%) with persisting ultrasound abnormalities after primary 
and secondary ultrasound screening underwent surgery to remove the 
tumour.  
 
3D ultrasound combined with power Doppler had a sensitivity of 100%, 
specificity of 99.4%, positive predictive value of 20% and negative 
predictive value of 100%.  
Study N° 11 
(Lux et al., 2005) 
 
 
Prospective follow-up study to evaluate the influence of 
risk and genetic counselling on use of early cancer 
detection. 556 BRCA 1/2 gene carriers attended primary 
consultation in the interdisciplinary cancer clinic. Semi-
annular transvaginal ultrasound and pelvic examination 
was used. 
2+ At present it is not known if there is an individual benefit of an intensified 
early cancer detection programme for women at risk. No studies present a 
decrease of mortality through early detection especially for women with a 
family history of breast / ovarian cancer.   
 
Early cancer detection can prove to be a psychological strain for women at 
risk and a financial burden to the health system but it is a less invasive 
option than prophylactic surgery. 
Study N° 12 
(Marchetti et al., 
2002) 
Aim of study to verify if ultrasound as a first level test 
can be trusted as a screening test for ovarian cancer. 
4,350 women with an average age of 49 years underwent 
ultrasound examination. 
2++ 29 patients had ultrasound findings indicative of malignant lesions and 
147 findings of benign lesions. 2 patients were found to have malignant 
lesions, both of which were detected by ultrasound.  
 
Sensitivity of 100%, Specificity of 99.81% and positive predictive value 
of 20%.  Ultrasound offers an inexpensive, safe and imaging modality 
capable of picking out possible or malignant ovarian lesions. 
Study N° 13 
(Menon et al., 
2000) 
 
 
To assess the performance of ultrasonography in a 
multimodal ovarian cancer screening strategy. 
 
741 Postmenopausal women, >45 years with a raised 
CA125 underwent a pelvic ultrasound. Scans classified 
as normal, abnormal or equivocal based on ovarian 
morphology and size. 
2++ The sensitivity for detection of ovarian cancer of different ultrasound 
criteria was 100% for abnormal morphology, 89.5% for abnormal volume 
and 84% for complex morphology.  
 
The highest specificity (97%) and positive predictive value (37.2%) was 
achieved using complex morphology. A variety of ultrasound criteria can 
achieve high sensitivity, specificity and positive predictive value for index 
cancers. 
Study N° 14 
(Miller et al., 2001) 
Decisions on policies for screening for ovarian cancer 
require that information upon health-related quality of 
life (HRQL) and cost-effectiveness (CE) be available. 
A framework within which both HRQL and cost-
effectiveness of ovarian cancer screening can be 
assessed is presented in this study. 
1+ Assessment of quality of life and costs within a large screening trial is not 
a simple exercise. There is potential for significant respondent burden, 
which could adversely affect the main trial processes.  Costs are still being 
collected from the US Prostate, Lung, Colon and Ovary Trial. 
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Study N° 15 
(Van Nagell Jr. et 
al., 2007) 
 
 
To determine the efficacy of annual transvaginal 
sonography (TVS) as a screening method for ovarian 
cancer. 
 
Annual screening was performed on 25,327 
asymptomatic women above 50yrs of age or above 25yrs 
of age with a family history of ovarian cancer. Persisting 
abnormal TVS had a serum CA125, tumour morphology 
indexing and Doppler flow ultrasound. 
2++ 364 patients with persisting TVS abnormalities underwent surgical 
intervention with 35 primary invasive ovarian cancers detected. 28 Stage 
I, 8 Stage II and 8 Stage III. TVS screening was associated with a 
sensitivity of 85%, specificity of 98.7%, positive predictive value of 
14.01% and negative predictive value of 99.9%. 
 
TVS screening when performed annually is associated with a decrease in 
stage at detection and a decrease in case-specific ovarian cancer mortality. 
TVS screening does not appear to be effective in detecting ovarian cancer 
in which ovarian volume is normal. 
Study N° 16 
(Pavlik et al., 2000) 
The effect of ovarian cancer screening on survival is 
enabled by women who continue to actively participate 
in screening. This study examines factors that affect 
participation. 
 
Background, health history and reasons for participating 
in transvaginal ultrasound screening were collected from 
13,963 women above 50yrs old by means of a 
questionnaire. 
2++ The probabilities of a return screen at 1,2,5 and 7.5 years were 77.8%, 
72%, 58.7% and 50.6% respectively. A total of 96% of return visits 
occurred within 2yrs.  Perceived family history was not observed to affect 
continuation. However, abnormal findings were associated with a 
shortened participation.  
 
High levels of continuation in ultrasound screening indicate that women 
take this disease seriously and demonstrate that this disease is of 
consequence to them. 
Study N° 17 
(Roupa et al., 2004) 
The aim of this study was to evaluate the combination of 
serum CA125 and TVS as a screening procedure for 
ovarian cancer in pre and postmenopausal women. 
2+ TVS and increased CA125 levels detected 120 women with    ovarian 
cancer. A sensitivity of 81.7%, specificity of 100% was achieved in 
predicting ovarian cancer.  By combining TVS and CA125 an accurate 
prediction for the presence of ovarian cancer may be achieved. 
Study N° 18 
(Saito et al., 2005) 
A new efficient screening for ovarian cancer based on a 
combination of two tumour markers, CA602 and CA546 
is reported in this study. When the level of one or both 
tumour markers exceeded the cut-off, the individual was 
referred for secondary tests including TVS and CA125. 
2+ A combination of CA602 and CA546 increased the detection rate of 
ovarian cancer from 77.8% to 85.8%, compared with CA602 alone, 
demonstrating that the combination assay was effective at detecting 
ovarian cancers. 
Study N° 19 
(Salsman et al., 
2004) 
Clinical, demographic and psychological characteristics 
of new, asymptomatic participants in a transvaginal 
ultrasound-screening programme for ovarian cancer. A 
cohort of 312 women were assessed immediately before 
undergoing a TVS for ovarian cancer. 
2++ Analysis revealed that the ovarian cancer screening group characterised 
not only by more ovarian cancer specific distress and a more extensive 
family history of ovarian cancer but also by less optimism and less 
knowledge of ovarian cancer risk factors. 
 
88.3% of women invited to undergo ovarian cancer screening provided 
informed consent. Those who declined screening cited reasons as too busy 
or too stressed. 
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Study N° 20 
(Sato et al., 2000) 
 
 
Cohort study of 183,034 women participating in ovarian 
cancer screening programme. Purpose of study to 
summarise and evaluate screening results for the last 
10yrs with respect to ovarian carcinoma diagnosis and 
risk factors. TVS was limited to a 30 second 
examination for identification of a pelvic mass above 
30mm in size. 
2+ Surgery was performed on 324 participants with 22 primary tumours and 
2 metastatic tumours detected. 
 
Of the 22 tumours, 17 (77.3%) were classified as Stage 1. These results 
are significant in that 77.3% of the primary ovarian carcinomas found 
during the screening were of curable Stage 1. 
Study N° 21 
(Stirling et al., 
2005) 
To assess the effectiveness of annual ovarian cancer 
screening using TVS and CA125 in detecting 
presymptomatic ovarian cancer in women at increased 
genetic risk. 
 
A cohort of 1,110 women at increased risk were 
screened.  553 were moderate-risk individuals and 557 
were high-risk individuals.  
2+ 13 epithelial ovarian malignancies developed in the cohort. 10 tumours 
were detected at screening – three at Stage I, two at Stage II, four at Stage 
III and one at Stage IV.  
Of the three cancers not detected by screening two were stage III and one 
was stage IV. 
 
Annual surveillance by TVS and CA125 is ineffective in detecting 
tumours at a sufficiently early stage to influence prognosis.  With a 
positive predictive value of 17% and a sensitivity of less than 50%. 
Study N° 22 
(Tailor et al., 2003) 
 
 
To assess the use of TVS as a screening test for familial 
ovarian cancer and secondarily, to determine the 
potential role of CA125 levels in the screening 
procedure. 2500 asymptomatic women with at least one 
close relative who had developed ovarian cancer were 
studied. 
 
2+ Women were aged 17 to 78 with 65% premenopausal and 26% 
postmenopausal. 104 screens gave a positive result with 11 cancers 
detected. One additional cancer was reported within 12 months of the last 
scan and classified as a false-negative screen result. Eight cancers were 
reported at follow-up (1-9 years after last scan). 
 
15 of the 20 cancers occurred in premenopausal women. Ultrasound 
sensitivity was 92% with a specificity of 97.8%.  TVS can effectively 
detect ovarian cancer and tumours of borderline malignancy in women 
with a family history of the disease. 
Study N° 23 
(Zhang et al., 2007) 
Artificial neural network (ANN) as a modelling tool has 
demonstrated its ability to assimilate information from 
multiple sources and to detect subtle and complex 
patterns. ANN has been evaluated in this study for its 
performance in detecting early stage ovarian cancer 
using multiple serum markers. 
 
100 apparently healthy women, 45 with benign 
conditions arising from the ovary and 55 invasive 
epithelial ovarian cancer patients.  
2+ The combined use of multiple tumour markers though an ANN improves 
the overall accuracy to discern healthy women from patients with early 
stage ovarian cancer. 
 
At a fixed specificity of 98%, the sensitivities for ANN and CA125 alone 
were 71% and 46% respectively. 
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APPENDIX D 
Table of Ovarian Cancer Cases diagnosed at Milton Keynes Hospital NHS Foundation Trust 
Case 
No 
Menopausal 
Status 
 Age at 
Diagnosis 
Presenting Symptoms Diagnostic Findings CA125 History of Cancer FIGO 
1 Postmenopausal  65 Adenocarcinoma in right pleural 
effusion 
Pelvic mass. Omentum replaced with tumour. Ascites. 541  4 
2 Postmenopausal  50 Weight loss. Pelvic pains. 
Abdominal swelling. 
Bilateral pelvic masses. Ascites. 4403  2 
3 Postmenopausal  58 Abdominal distension and epigastic 
pain. 
Large ovarian mass. Inguinal lymph node. Omental 
spread. 
1564  3 
4 Postmenopausal  62 Intermittent right sided pain.  Bilateral ovarian and tubal malignancies. Omental 
spread. Involvement of sigmoid. Peritoneal spead. 
1136  3 
5 Postmenopausal  60 Pelvic pain / swelling. Previous 
hysterectomy. 
Complex irregular mass in right adnexa 8cmx7cm. 90  3 
6 Postmenopausal  60 Abdominal swelling. Pelvic mass. 41  2 
7 Postmenopausal  60 Abdominal pains. Pelvic mass. No spread. 43  1 
8 Postmenopausal  60 Abdominal swelling. Localised pelvic mass. No spread. 90  1 
9 Postmenopausal  57 Pleural effusion. Abdominal 
swelling. 
Cystic / solid pelvic mass on ultrasound. Ascites. Pleural 
effusion. 
599  4 
10 Postmenopausal  63 Abdominal pain. Change in bowel 
habit. 
Ascites. Peritoneal metastatic disease. Omental 
thickening. 
2500 Mother and 1st 
cousin breast ca. 
4 
11 Postmenopausal  60 Pelvic discomfort. Change in bowel 
habit. 
Enlarged ovary containing a simple cyst on ultrasound. 
Ascites. Bilateral disease on CT. 
547  3 
12 Premenopausal  50 Abdominal discomfort Large complex ovarian cyst. No spread. 31  1 
13 Postmenopausal  58 Pain and swelling in abdomen. Large pelvic mass. Bowel involement. 1000  3 
14 Postmenopausal  59 Abdominal discomfort. Large pelvic mass.  40  1 
15 Postmenopausal  77 Change in bowel habit. Weight loss. 11cmx8cm solid mass infiltrating the rectum on CT. 
Ascites and liver metastasis.  
1054  4 
16 Premenopausal  43 Pelvic pains. Complex pelvic mass. 11 Mother and sister 
have had ovarian 
cancer. 
2 
17 Postmenopausal  53 Pelvic pains. Palpable mass. Solid / Cystic pelvic mass in pelvis on U/S and CT. No 
distal spread. 
97  1 
18 Postmenopausal  57 Abdominal distension. Pelvic pain.  Ascites. Pelvic mass. 187 History of Cervical 
cancer. 
2 
19 Postmenopausal  63 Mass felt in pelvis. ? Ovarian cyst. Pelvic tumour. Omental thickening. 120  3 
20 Postmenopausal  55 Abdominal discomfort. Right leg 
pains. 
Pelvic mass. Malignant cells in peritoneum. 47  3 
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21 Postmenopausal  78 Abdominal pain. Change in bowel 
habit. 
Pelvic mass. Peritoneal spread. Ascites. Pleural effusion. 290  4 
22 Postmenopausal  78 Shortness of breath. Abdominal 
distension. 
Loculated cystic area 11cmx6cm on CT. Pleural 
effusion. Omental thickening. 
1325  4 
23 Postmenopausal  87 Postmenopausal bleeding. Pelvic mass. Ascites. Liver metastases disease. Bowel 
metastases. 
396  4 
24 Postmenopausal  65 Abdominal pains. Pelvic mass on CT and U/S. Ascites and Omental 
thickening. Liver metastasis.  
84  4 
25 Postmenopausal  74 Change in bowel habit. Complex pelvic mass. Ascites. 115  2 
26 Postmenopausal  60 Abdominal bloating Complex pelvic mass. No spread. 153  1 
27 Postmenopausal  70 Pelvic pain. Pelvic mass. Omental thickening. 92  2 
28 Postmenopausal  63 Postmenopausal bleeding. Complex pelvic mass. Omental spread. 98  3 
29 Postmenopausal  52 Right iliac fossa / pelvic pain. Bilaterally enlarged ovaries on CT. Peritoneal spread.  20  3 
30 Postmenopausal  58 Abdominal pain / discomfort. 
Urinary symptoms. 
Complex pelvic cyst.            363  1 
31 Postmenopausal  65 Abdominal distension. Complex pelvic mass. Periaortic lymph node. 286  1 
32 Postmenopausal  67 Abdominal distension and pelvic 
mass felt. 
Multi-cystic mass arising from pelvis and solid 
components. Enlarged nodes. Liver mets. 
529  4 
33 Postmenopausal  83 Abdominal distension and urinary 
frequency. 
US shows 12cmx8cm cystic lesion with irregular wall 
thickening, ascites and liver mets. 
1379  4 
34 Postmenopausal  75 Postmenopausal bleeding. Complex pelvic mass. Spread to small bowel. 4924  3 
35 Postmenopausal  72 Urinary symptoms and frequency.  Abdominal mass. Localised 16cm tumour. 51 Family history of 
breast cancer. 
1 
36 Postmenopausal  75 Lower abdominal pains.  6cm Pelvic mass. 471  1 
37 Postmenopausal  74 Abdominal pain and anaemia.  Cystic / solid pelvic mass on US and CT. Possible liver 
mets.  
2355  3 
38 Premenopausal  47 Pelvic discomfort. Change in bowel 
habit. 
Cystic / solid pelvic mass 12cm x 14cm. One mass open. 176 Breast cancer 2 
39 Premenopausal  30 Abdominal distension and shortness 
of breath. 
Large mass filling abdomen with cystic and solid 
components. Ascites / pleural effusion. 
268  4 
40 Postmenopausal  53 Abdominal pain Complex pelvic mass 6-8cm in size. Omental spread. 287  2 
41 Postmenopausal  71 Abdominal swelling. Weight loss. Pelvic tumour. Ascites and bowel involvement. Deposits 
under the diaphragm. 
4179  3 
42 Postmenopausal  73 Pelvic pain. Irregular bleeding. 15cm Complex cystic / solid pelvic mass on US and CT. 
Lymphadenopathy. 
5036  2 
43 Postmenopausal  79 Abdominal swelling. Ovarian tumour with extensive ascites. 431  3 
44 Postmenopausal  59 Lower abdominal pains.  Complex ovarian mass 12cmx8cm. No distal spread. 2225  1 
45 Postmenopausal  78 Lymphoedema. Pelvic mass on CT and US. Lymphadenopathy.  378  3 
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46 Premenopausal  44 Pelvic pain. H/O endometriosis. Localised pelvic mass. No spread. 5000  1 
47 Postmenopausal  59 Postmenopausal bleeding. Complex pelvic cyst. No other spread. 7  1 
48 Postmenopausal  63 Weight loss. Pelvic discomfort. Ascites, peritoneal mets, lung mets. No ovarian mass 
detected. 
1384  4 
49 Premenopausal  39 Abdominal pain. Urinary symptoms. Large pelvic mass. Cervical lesion. 413  2 
50 Premenopausal  52 Irregular vaginal bleeding. Pelvic 
pain. 
Localised pelvic mass. No spread. 9  1 
51 Postmenopausal  57 Abdominal distension.  Pelvic mass. Ascites. Adhered to bowel and liver. 
Omentum replaced with tumour. 
910 Mother breast and 
bowel Ca. Cousin 
breast Ca. 
4 
52 Premenopausal  53 Postmenopausal bleeding. Complex pelvic mass. Cancer of ovary with spread to 
uterus and cervix. 
500  2 
53 Postmenopausal  68 Change in bowel habit. Weight loss. Ascites. Omental thickening. Pelvic mass. Pleural 
effusions. Liver metastases. 
182  4 
54 Postmenopausal  51 Postmenopausal bleeding. Bilateral ovarian masses. Extensive peritoneal seedlings. 866  3 
55 Premenopausal  40 Abdominal distension.  Bilateral ovarian masses. Ascites and omental 
thickening.  
794  3 
56 Postmenopausal  71 Abdominal bloating. Complex abdominal mass. Omental spread. 456  3 
57 Postmenopausal  60 Lower limb swelling. Abdominal 
mass felt. 
Complex solid mass on CT 9cmx8cm. Peritoneal 
seedlings. 
1370  4 
58 Premenopausal  54 Abdominal distension. Pain. Large abdominal mass. Ascites. Pleural effusion.  21  4 
59 Premenopausal  39 Right iliac fossa / pelvic pain. Bilateral ovarian masses. One mass opened - one closed. 891  2 
60 Premenopausal  44 Pelvic pain.  Bilateral ovarian tumours. Omental spread 155  4 
61 Postmenopausal  61 Abdominal discomfort. Vaginal 
bleeding. 
Abdominal mass. Omental nodular disease spread. 800  4 
62 Postmenopausal  55 Abdominal distension. Change in 
bowel habit. 
Complex abdominal mass. Omental spread. 5000  4 
63 Premenopausal  52 Irregular vaginal bleeding. Pelvic 
pain. 
Fibroid uterus misdiagnosed on US. CT demonstrates 
complex ovarian mass. Ascites. 
978  3 
64 Premenopausal  49 Abdominal pain / distension Solid / necrotic pelvic mass. No spread. 58  1 
65 Postmenopausal  57 Abdominal distension and pain.  15cm Pelvic tumour involving the rectum and sigmoid 
colon. Lung metastatic disease. 
325 Bilateral breast 
cancer. BRCA1 
Carrier. 
4 
66 Postmenopausal  71 Abdominal distension. Change in 
bowel habit. 
Pelvic mass. Ascites. Pleural effusion. 1596  3 
67 Postmenopausal  75 Abdominal discomfort and 
distension. 
Pelvic Mass. Ascites. Mesenteric nodularity. Pleural 
effusion. 
364  4 
68 Postmenopausal  56 Weight loss/change in bowel habit. Complex pelvic mass. Liver Metastatic disease. 555  4 
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69 Postmenopausal  57 Abdominal swelling. Change in 
bowel habit. 
10cm Pelvic mass. 500  1 
70 Premenopausal  37 Pelvic pains. Irregular vaginal 
bleeding. 
13cm complex pelvic mass. Ascites. No distal spread. 167  2 
71 Postmenopausal  71 Shortness of breath. Abdominal 
distension. 
Liver mets, pleural effusion. Cystic / solid pelvic mass 
on US. 
629  4 
72 Postmenopausal  53 Pelvic pain.  Palpable mass. Complex pelvic mass 10cmx14cm. No spread. 60  1 
73 Postmenopausal  59 Mass felt in pelvis by GP.  Complicated pelvic mass / cystic lesion. 48  1 
74 Premenopausal  41 Altered bowel habit. LIF fullness. Localised pelvic mass. No spread. 78  1 
75 Premenopausal  48 Left iliac fossa tenderness. Unwell. Complex multilocular cystic lesion on US.  No spread. 120  1 
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APPENDIX E 
Table of Suspected Ovarian Cancer Cases diagnosed at Milton Keynes Hospital NHS Foundation Trust 
Case No Menopausal 
Status 
 Age Imaging 
Modality 
Diagnostic Findings / Suspected Pathology Outcome 
1 Premenopausal  43 US Complex adnexal mass 10cm x 9cm x 6cm with solid areas 
within. 
MRI - confirms dermoid / haemorrhagic cyst. 
2 Premenopausal  40 US Large multiseptated pelvic mass  HISTOLOGY - Benign ovarian cyst with 
haemorrhagic component 
3 Premenopausal  39 MRI Large ovarian mass with cystic and solid components. Suspected 
ovarian neoplasm. 
HISTOLOGY confirms bowel neoplasm. 
4 Premenopausal  37 US Complex right ovarian mass 7cm x 5cm x 4cm with internal 
echoes and thickened septae. 
HISTOLOGY -endometriotic cyst. 
5 Premenopausal  47 CT Complex adnexal mass on CT ? Fibroid ? Ovarian Ca MRI - Confirms fibroid. 
6 Premenopausal  49 US Complex multilocular cyst on US CT - 1 month later no abnormality detected. 
7 Premenopausal  29 CT 9cm multilocular cystic lesion with solid components and small 
volume of free fluid on CT 
US - Benign cyst - decreased in size 2 weeks later 
8 Premenopausal  53 US Complex heterogenous mass 8cm x 7cm x 5cm. Unable to 
exclude malignancy. 
HISTOLOGY -mucinous cystadenoma. No 
malignancy. 
9 Postmenopausal  72 US Large complex cystic ovarian lesion on US CT - dermoid cyst 
10 Premenopausal  48 US & CT 19cm complex mass in pelvis on US and CT. ? Fibroid ? Ovarian 
Ca 
MRI - fibroid. 
11 Premenopausal  49 US & CT Complex solid masses bilaterally on US and CT. MRI - enlarged ovaries with benign functional cysts. 
12 Postmenopausal  71 US & CT Complex multilocular solid mass on US 9cmx 6cm confirmed by 
CT as ?Ca. 
HISTOLOGY - benign cyst. 
13 Premenopausal  45 US & CT Complex solid pelvic mass. No distal spread. Malignancy 
suspected. 
HISTOLOGY -benign ovarian cyst with haemorrhagic 
component 
14 Postmenopausal  83 US Large 25cm cyst with septations and wall irregularity on US. HISTOLOGY - Benign cyst 
15 Premenopausal  30 US & CT Bilateral complex ovarian cysts on US and CT. MRI - endometriotic cysts. 
16 Premenopausal  30 US Complex cyst with internal septae and solid areas.  HISTOLOGY - Haemorrhagic cyst following 
laparoscopy. 
17 Premenopausal  32 US & CT Complex solid pelvic mass on US and CT. HISTOLOGY - Benign endometriotic cyst 
18 Premenopausal  38 CT Multilocular cystic mass in pelvis with solid components. 
Possible bowel involvement. 
HISTOLOGY - confirms benign ovarian fibroma - 
25cm in diameter. 
19 Premenopausal  16 US & MRI Bilateral complex ovarian masses with cystic and solid areas 
within on US and MRI. 
US - 3 months time no longer present. 
20 Premenopausal  32 US Irregular complex cystic area in pelvis with solid areas - US. CT - dermoid cyst 
21 Premenopausal  33 US & CT Enlarged ovary with heterogenous and cystic lesions on US. CT 
confirms solid / cystic mass. 
HISTOLOGY - Endometrioma. 
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22 Premenopausal  26 ALL 18cmx15cm Pelvic mass with multiple septations and solid 
components on US / CT and MRI. 
HISTOLOGY - Mucinous cystadenoma. 
23 Premenopausal  44 US Solid complex mass on US 7cmx6cm.  CT and MRI required to confirm haemorrhagic / 
endometrioma. 
24 Premenopausal  31 US Complex ovarian cyst on US with raised CA125. ?Ca MRI - dermoid cyst 
25 Premenopausal  46 US Solid ovarian mass on US.  MRI - large uterine fibroid. 
26 Premenopausal  36 US Large pelvic mass measuring 32cmx16cmx27cm. ? Fibroid on 
US. Unable to exclude Ca. 
MRI - confirms large uterine fibroid. 
27 Postmenopausal  56 US Solid / cystic mass on US 7cmx3cm. MRI and CT - confirm dermoid cyst. 
28 Premenopausal  27 US Enlarged complex appearing right ovary measuring 7cmx6cm. CT confirms pelvic abcess 
29 Premenopausal  22 US Complex ovarian mass on US.  US in 3 months now simple cyst. 
30 Premenopausal  44 US Complex mass in right adnexa 10cmx9cm. HISTOLOGY - Endometrioma. 
31 Premenopausal  36 US Irregular adnexal mass with solid components.  US in 3 months functional cysts. 
32 Premenopausal  41 US Complex adnexal mass on US 7cmx4cmx9cm. Unable to 
characterise. 
MRI - Endometrioma 
33 Premenopausal  27 US Complex midline pelvic mass on US with solid components 
measuring 7cmx8cm. 
MRI confirms fluid collection. 
34 Premenopausal  29 US Complex ovarian mass on US measuring 6cm x 5cm. Unable to 
characterise. 
MRI - Dermoid cyst 
35 Premenopausal  38 US Abdominal cystic mass filling cavity. ?Endometrioma 
?Malignancy 
HISTOLOGY - Benign cyst. 
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APPENDIX F 
Email Contact with Cost Accountant at Milton Keynes Hospital  
NHS Foundation Trust 
 
From: Catharell Caroline (RD8) Milton Keynes Hospital 
Sent: Tue 14/07/2009 11:29 
To: Nicholson Simon (RD8) Milton Keynes Hospital 
Subject: RE: NHS Costings 
Simon, 
  
The 2008/9 cost for an Elective Q49.1 (which links to HRG4 code MA10Z - Upper Genital Tract 
Laparoscopic / Endoscopic Minor Procedures) is £1,235 which inflated by 1.7% to get to 2009/10 cost 
would be £1,256. 
  
Hope this helps, 
  
Caroline Catharell 
Cost Accountant 
Milton Keynes Hospital NHS Foundation Trust 
Tel: 01908 826565 
  
-----Original Message----- 
From: James Anne-marie (RD8) Milton Keynes Hospital  
Sent: 02 July 2009 11:47 
To: Nicholson Simon (RD8) Milton Keynes Hospital 
Cc: Catharell Caroline (RD8) Milton Keynes Hospital 
Subject: RE: NHS Costings 
  
Simon 
  
The OPCS4 code for excision of an ovarian cyst is as follows: 
  
Q49.1 – Endoscopic extirpation of lesion of ovary 
  
Anne-Marie 
Anne-Marie James | Clinical Coding Manager|  01908 660033 (ext 2630) or 01908 (24)3930 
-----Original Message----- 
From: Nicholson Simon (RD8) Milton Keynes Hospital  
Sent: 02 July 2009 10:57 
To: James Anne-marie (RD8) Milton Keynes Hospital 
Subject: FW: NHS Costings 
  
Dear Ann-marie 
  
Could you provide me with a OPCS code for a laparoscopy performed by a gynaecologist for removal of 
a cyst/lesion please. I imagine an overnight stay would also be required. 
  
  
Many thanks.    
Simon Nicholson 
Reporting Sonographer / Research Fellow 
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APPENDIX G 
UK Familial Ovarian Cancer Screening Study 
Complex Ovarian Morphology Classification 
 
 
 
 
